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Abstract 
The aims of the study were to investigate occupational exposure and the exposure routes of coal tar 
creosote, and to evaluate the suitability of methods for monitoring occupational exposure to the PAHs in 
creosote.   
 
The composition of four creosotes used in Finland was studied by gas chromatography/mass 
spectrometry. Creosotes contain polycyclic aromatic hydrocarbons (over 60%), phenols, and 
heterocyclic sulphur and nitrogen compounds. The mutagenicity of four creosotes and their chemical 
fractions was studied with the Ames Salmonella tests. All creosotes were mutagenic with Salmonella 
typhimurium TA98 in the presence of metabolic activation. The potency of the mutagenicity correlated 
with the content of benzo(a)pyrene in the creosotes. The mutagenicity of the creosotes was nevertheless 
higher than that of the distillated fractions containing more BaP than the creosotes.    
 
The kinetics of naphthalene was investigated in two volunteers after intake by oral, dermal and 
respiratory routes. The kinetic pilot study confirmed that naphthalene is absorbed into the body by all 
routes in humans, and that the metabolism is route-specific.  
 
Airborne concentrations of vapours and particulate PAHs were measured in two impregnation plants 
and at five work sites where impregnated wood was handled. The workers were exposed via the lungs to 
the airborne impurities consisting mainly (over 95%) of vaporous compounds. The main compounds 
were naphthalene, its alkyl homologues, indene, phenol, benzothiophene and diphenyl. The total TWA 
concentration of the vapours ranged from 0.5-9.1 mg/m3 in the impregnation plants, and from 0.1-
11 mg/m3 in the handling of treated wood. The TWA airborne concentration of particulate BaP was low 
(0.01 µg/m3 and 0.02 µg/m3), except when the creosote or treated wood was heated.  
 
Concurrently with the monitoring of the air impurities, the urinary 1-OHN and 1-OHP concentration of 
six wood preservers and three assemblers handling treated wood was monitored during one work week. 
The arithmetic mean concentration of urinary 1-OHN in the impregnation plant workers was as high as 
in the assemblers (1330-1350 µmol/mol creatinine). The urinary 1-OHP concentration was 10 times 
higher in the impregnation plant workers (64 µmol/mol creatinine) than in the assemblers.  
 
The significance of the skin as a route of exposure was estimated from the daily output of the urinary 1-
OHN and 1-OHP and the daily inhaled uptake of naphthalene and pyrene. The results suggest that 50-
60% of the naphthalene uptake, and over 99% of the pyrene were absorbed percutaneously.  
 
Urinary 1-OHN and 1-OHP are better indicators of  total exposure to creosote than the measurement of 
airborne impurities, because they reflect also dermal exposure. The suitability of urinary 1-OHN and 1-
OHP as biomarkers of PAH exposure depends on how well they predict the uptake of other PAHs. More 
knowledge is needed to estimate whether urinary 1-OHP is a reliable indicator of dermal absorption for 
other PAHs, e.g. BaP. For occupational exposure and risk management purposes, one can assume that 
the relative dermal bioavailability of other PAHs is not higher than that of naphthalene and pyrene. 
 
National Library of Medicine Classification: WA 465, QV 627 
Medical Subject Headings: occupational exposure; creosote; coal tar; inhalation exposure; skin 
absorption; creosote/analysis; polycyclic hydrocarbons, aromatic; mutagens; mutagenicity tests; 
naphthalenes;  air pollutants; occupational; aerosols; biological markers  
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1-OHP 1-Hydroxypyrene, 1-pyrenol 
ACGIH American Conference of Governmental Industrial Hygienists 
ATD Alkali thermoionisation detector 
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CSM Cyclohexane soluble matter 
CTPV Coal tar pitch volatiles 
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GC Gas chromatograph 
HPLC High performance liquid chromatograph 
HRGC High resolution gas chromatograph 
IARC International Agency for Research on Cancer 
Log Kow Logarithm of octanol-water partition coefficient 
MMA Manual metal arch welding 
mmHg Millimeter mercury 
MS Mass spectrometry 
NIOSH National Institute of Occupational Safety and Health, USA 
OEL Occupational exposure limit 
OR Odds ratio 
PAH Polycyclic aromatic hydrocarbon 
ppm Parts per million 
PTFE Polytetrafluoroethylene 
S9 mix Supernatant (containing microsomal fraction) of rat liver homogenase induced 
with Arochlor-1254 and centrifuged at 9000g  
SCE Sister chromatid exchange 
SIR Standardised incidence ratio 
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Coal tar creosote is the oldest industrial wood preservative, having been employed throughout the world 
for almost 150 years. Creosote is a brownish-black, oily liquid, obtained by the fractional distillation of 
crude coal tars. Coal tars are by-products in the carbonisation of coal to coke or to town-gas 1. Creosotes 
contain hundreds of compounds and their composition can vary from batch to batch 2. The European 
Union (EU) regulates the contents of benzo(a)pyrene (BaP) (≤0.05% or ≤0.005% depending on the use) 
and water extractable phenols (≤3 %) in creosotes ( Directive 94/60/European Commission).  
 
The most serious health effect of coal tars is carcinogenicity. The International Agency for Research on 
Cancer (IARC) has stated that there is sufficient evidence that creosote oils are carcinogenic to 
experimental animals, but there is still limited evidence that creosotes derived from coal tars are 
carcinogenic in humans 2. Many studies have shown that polycyclic aromatic hydrocarbons (PAH) in the 
complex mixtures of coal tars are mainly responsible for their carcinogenic potential 3. The acute 
symptoms caused by creosote are mainly skin effects. These include cutaneous photosensitivity, 
irritation, pitch warts, and skin discoloration. In addition, irritation of respiratory tract and eyes has been 
reported. 
 
Until the end of the 1980s the exposure levels and hazards of PAH mixtures were estimated by 
atmospheric monitoring of coal tar pitch volatiles (CTPV) or BaP, and in the 1990s the analysis of 
individual PAHs became common 4. When biological monitoring of PAH metabolites was introduced 
for the estimation of exposure levels, it became apparent that air concentrations of PAHs alone are less 
valid indicators of PAH exposure, especially at work sites where coal tar products are used 5, 6. Skin 
contamination and percutaneous absorption of coal tar products has received only little interest before 
the 1990s.  
 
The impregnation of wood is the main use of creosote. All creosote used in Finland today is imported, 
but before the 1970s small amounts of creosote were obtained as a by-product of town gas production 
from coal. The workers in the impregnating plants comprise the occupational group with the highest 
exposure to creosote. Other exposed groups include the workers handling impregnated wood, such as 
assemblers repairing and constructing railroads, electrical and telegraph repairmen, stevedores, and 
workers handling creosote-contaminated soil. 
 
Data on exposure among creosote workers, especially those handling impregnated wood, is scanty 2. The 
aim of this study was to explore the level of occupational exposure among creosote workers, to assess 
the significance of skin absorption as a route of exposure, and to investigate whether the contents of BaP 
and PAHs in creosote are good surrogates for genotoxicity. Though the data of the present study 
describes the exposure situation at the end of the 1980s, the results are relevant in the estimation of 
long-term health effects. The latency period for carcinogenic chemicals is generally from 10 to 20 years. 
When assessing hazards for long-term effects, it would be important to know the levels of exposure 
retrospectively. 
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2. Production, Use and Composition of Creosotes 
2.1. Production 
When coal is carbonised to make coke or gas, crude coal tar is one of the by-products. Thus, production 
of coal tars is closely linked with the steel industry, because of the need for coke in steel making. 
Another major source of coal tar, gas manufacture by coal carbonisation, has declined rapidly since the 
1960s and 1970s due to increasing exploitation of natural gas  2. Crude coal tar is distilled either in high-
temperature (>700 °C) or low-temperature (<700 °C) processes. The distillation fractions of crude coal 
tars have been classified into seven fractions on the basis of their boiling ranges 2. Creosote oils used for 
timber preservation are blended products from the high-temperature processes. About 100 refineries in 
the world distil coal 1, and 9 companies in seven EU countries manufacture creosote 7.  
 
Only one coking plant operates in Finland, and it produces annually about 40 000 tonnes of coal tar as a 
by-product 8. The coking plant does not, however, distil the tar further. Coal tar is mainly exported, and 
a small portion is burnt. Small amount of coal-tar products were formed when gas was produced from 
coal in Finland, but the latest plants were closed at the beginning of the 1970s. At present, all creosote 
used in Finland is imported. 
 
2.2. Use 
Creosote is almost solely used for wood impregnation world-wide1, and it is mainly used by industrial 
impregnation plants. In the EU countries, mostly in the United Kingdom (UK) and Ireland, 10% of 
creosote is used by individual consumers 7. According to the Finnish Wood Preserving Association, 
since 1997, creosote finds application only in industrial wood preservation in Finland, when the last 
paint type creosote (carbolineum) was phased out. All creosote impregnation plants use pressure 
treatment in Finland. In the USA, about 1/3 of the creosote impregnation cylinders (all together 102 
cylinders) were non-pressure tanks in 1996 9. Industrial impregnators primarily treat timber for use as 
railway ties, telegraph and power poles and piles. Other impregnators and individual users have treated 
timber by brushing, dipping, spraying or soaking. In small enterprises, poles, fence posts, etc., have also 
been treated by dipping them into open tanks containing hot creosote in small enterprises 10.  
 
In addition, coal tar creosote has been blended with soaps to form a water-miscible material that can be 
used as an insecticide, herbicide, fungicide, animal repellent and animal dip 11, 12. Coal tar, which is 
classified as creosote in the literature, is also used for the treatment of certain skin diseases, e.g. 
psoriasis 13.  
 
All creosote used in Finland is imported. The first batches of creosote were imported in barrels from the 
USA, and up until the 1980s, the bulk was imported from Poland and the Soviet Union. Since 1980, 
Denmark, Poland and Germany have also delivered creosote to Finland (Finnish Wood Preserving 
Association). The volume of pressure-impregnated wood produced in Finland was 280 000 m3 in 1998 
(1997: 270 000 m3); this total was made up of sawn goods 180 000 m3, poles 83 000 m3, and railway ties 
22 000 m3. For the total quantity of impregnated wood, the proportion of creosote impregnation was 
24%, salt impregnation 75% and organic impregnants 1% in 1998. The export of impregnated poles 
totalled 44 991 m3 in 1998 14. The consumption of creosoted wood was 1 million m3 in the EU member 
states in 1990 7 and 2.4 million m3 in the USA in 1996 9. 
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Since 1980 there has been a declining trend in the amount of creosote imported to Finland (Table 1). 
The total sale of creosote in the EU countries was 88 500 tonnes in 1995 the main users being the UK 
and Spain 7. The USA produced 291 800 tonnes of creosote oil and its solutions in 1996 9, and it has 
been estimated that over 106 tonnes/year of creosote is used as wood preservative world-wide 1. 
 
Table 1. The amounts of creosote imported to Finland 
 
Year Tonnesa
1940 0.2 
1950 2.7 
1960 8 500 
1970 13 400 
1980 19 300 
1985 11 700 
1990 5 000 
1995 6 300 
  a) The Finnish Wood Preserving Association 
 
2.2.1. Regulations 
The manufacture, import, delivery and use of protective chemicals such as wood preserving chemicals 
are controlled by national regulations in Finland (Table 2). Wood preserving chemicals must be 
submitted to an advanced approval and notification process carried out by the Ministry of the 
Environment. According to the new directive on biocidal products, the authorisation of biocides will be 
harmonised in the EU member states (Directive 98/8/European Commission on Biocidal Products).  
 
The marketing and use of creosote and preparations containing creosote, as well as creosote-treated 
wood, is restricted in Finland and in the EU member states that have ratified Directive 94/60/European 
Commission (Table 2). Finland implemented the Directive in 1995. According to the directive, creosote 
containing  more than 50 ppm (0.005 weight-%) BaP and 3 weight-% water extractable phenols may not 
be used for wood treatment, and wood so treated may not be placed on the market. However, creosote 
may be used for wood treatment in industrial installations if it contains BaP less than 0.05%, and wood 
treated with such creosote can be used only for industrial applications. The use of wood treated with 
creosote is prohibited inside buildings, in contact with plants or food, and on playgrounds. 
 
Classification regarding the carcinogenicity of creosote is based on the content of benzene and BaP 
(Table 2). The content of BaP in the creosotes used at present in Finland is usually below 50 ppm (the 
Finnish Wood Preserving Association). Most, but not all, of the producers in the EU member states are 
selling creosotes which contain less than 50 ppm BaP 7. Lowering of the allowed concentration of BaP 
in creosotes because of the hazards caused by skin contact of consumers, especially of children, with 
creosote impregnated timber is currently being discussed in the EU 7. 
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Table 2. Regulations on the authorisation and marketing of creosotes. 
 
Finnish regulation Background Summary of the content 
Approval of use   
Chemical Act (744/1989) on 
Protective Chemicals  
National regulation Protective chemicals such as wood preserving chemicals are not 
allowed to be manufactured, imported, delivered or used without an 
advance approval 
 
Council of State Decrees 
466 and 467/2000 on Biocidal 
Products 
Directive 98/8/European 
Commission on Biocidal 
Products 
Biocidal products, e.g. wood-preservatives, should not be placed on 
the market for use unless they have complied with the requirements 
of the Directive in the EU member states 
 
Restriction, 
Labelling and  packaging 
  
Council of State Decrees  
1405/1995 on the restriction on the 
marketing and use of creosote and 
wood treated with it 
Directive 94/60/European 
Commission 
Creosote containing ≥ 50 ppm BaP may not be used for wood 
treatment. However, creosotes may be used for wood treatment  in 
industrial installations if they contain BaP at the concentration of less 
than 0.05% by mass. Wood treated with such creosote can be used 
for industrial applications only. Use of wood treated with creosote is 
prohibited inside buildings, in contact with plants or food, and on 
playgrounds. 
 
Decision of the Ministry of Social 
Affairs and Health 1059/1999 on 
classification, packaging and 
labelling of dangerous substances 
Directive 94/69/European 
Commission 
Classification of certain mixtures including creosote is based on the 
content of benzene and BaP. If the content of benzene is below 0.1 
weight-% and that of BaP is below 0.005weight-%, classification of 
creosote as a carcinogen is not necessary 
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2.2.2. Impregnation process 
The preservative value of less refined coal tar products was known as early as 1680. The full-cell 
process was patented in 1828. This method promoted the usage of coal tar creosote and, following 
development of the empty-cell process, creosote impregnation became profitable by 1920 15. In this 
empty cell process (the Rüping process), creosote is injected into the wood under high pressure and 
temperature conditions. To complete the process, the pressure is released and the cylinder drained. In 
this process the excess preservative is removed from the wood cells in the final vacuum phase 16. Prior 
to impregnation, creosote is pumped from the storage tanks into tanks where it is preheated to 100-
110°C. The Rüping process used in the Finnish impregnation plants has an initial pressure of 200-500 
kPa prior to flooding of the cylinder with creosote 17, 18. The final vacuum phase generally lasts from 1 
to 3 hours, but to minimise the staining, the final vacuum can last up to 18 hours. During the cold 
seasons the timber may be warmed before impregnation e.g. with preheated creosote. This contributes to 
the penetration of creosote into the timber and reduces draining after impregnation (VR Group Ltd). 
 
2.3. Properties and composition 
2.3.1. Quality specifications 
Several distillation fractions (from low- and high-temperature processes) of coal tars have been called 
creosote oils. According to the Decision of the Ministry of Social Affairs and Health 164/1998, creosote 
oils have six numbers in the Chemical Abstracts Service registry (CAS). These products differ in their 
boiling ranges and thus also in their composition. In Finland, the creosotes used for wood impregnation 
are defined by the CAS numbers 8001-58-9, 90640-80-5 (anthracene oil) and 61789-28-4.  
 
CAS number 8021-39-4 is applied to a beechwood creosote which contains many phenolic 
compounds19. When the use or the health effects of creosote are described in the literature, it is not 
always clearly stated if the properties described refer to coal tar or to beechwood creosote. 
 
The creosotes used in timber preservation are classified in terms of specification tests which are given in 
standards, e.g. British standard 144/1990, the American Wood-Preservers’ Association standards P1 and 
P2, and Western European Institute for Wood Preservation for creosote grades A, B and C (Table 3). 
 
Technical standards include only ranges for physical characteristics, such as boiling point ranges, 
relative density, etc. Therefore there may be significant compositional variation between creosote oils, 
depending on several factors. In fact, most of the large-scale users have developed their own detailed 
specifications in relation to the boiling curves and the concentration of specific components in the 
creosote. In the Nordic countries, creosote-impregnated wood may contain different amounts of 
preservative, depending on the aimed use (Nordic Wood Preservation Council): AB-class (EN 351 
P8/R3) 90 kg/m3, A-class (EN 351 P8/R4) 135 kg/m3, and M-class (EN 351 P8/R5) 400 kg/m3. 
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Table 3. Specifications for creosote according to the standards issued by the Western European Institute 
for Wood Preservation. 
 
 Grade A Grade Ba Grade C 
Boiling range (°C) 200-400 235-400 300-400 
Relative density (g/ml) 1.04-1.15 1.02-1.15 1.03-1.17 
Water-content (weight-%) ≤ 1 ≤ 1 ≤ 1 
Water extractable phenols (%) ≤ 3 ≤ 3 ≤ 3 
Insoluble matter (%) ≤0.4 ≤0.4 ≤0.4 
Distillation fractions (weight-%) 
   ≤235°C 
   ≤300°C 
   ≤355°C 
 
≤10 
20-40 
55-75 
 
≤20 
40-60 
70-90 
 
- 
≤10 
65-95 
Content of  benzo(a)pyrene (%) ≤0.05 ≤0.005 ≤0.005 
Flash point (°C) >61 >61 >61 
Crystallization temperature (°C) ≤23 ≤23 ≤50 
Main use railway ties poles railway ties 
and poles 
a) The contents of naphthalene and its alkyl homologues are low 
 
 
2.3.2. Composition 
Creosotes are complex mixtures, and can contain over 30 different PAHs with a possible total PAH 
content of 85 weight-% 7. The main PAHs are naphthalene, alkyl naphthalenes, acenaphthene, fluorene, 
phenanthrene and anthracene. The concentration of BaP have ranged from 200 to 1600 ppm (4300 ppm 
in PAH fraction) (Table 4). In addition to PAHs, creosotes comprise tar acids (phenol, cresols, and 
dimethyl phenols), tar bases that are mainly nitrogen-containing heterocyclic compounds such as 
pyridine, quinolines, carbazoles, acridine and benzoquinolines 20, as well as heterocyclic compounds 
that contain sulphur and oxygen. The main nitrogen compounds are heterocyclic tar bases, but aromatic 
amines such as aniline, aminonaphthalenes, diphenylamines, aminofluorenes, and aminophenanthrenes 
have also been identified 21. Benzacridine and its methyl-substituted congeners have also been identified 
and quantified (0.001-0.02%) in creosotes 22.  
 
Before 1994, when the EU started to regulate the content of phenolic compounds in creosotes (≤3 %), 
creosotes could contain tar acids up to 20% (British standard BS144/73/2). Some large-scale purchasers 
had specified the ranges of the content of naphthalene and phenols in the oils they used, e.g. 
telecommunication companies in Germany and France used poles impregnated with oil containing 3-6 
volume-% and ≥ 6 volume-% of tar acids, respectively 20. The former Finnish State Railways required 
the content of tar acids in creosotes to be from 3 to 9% (Finnish State Railways, Standard 1096/1956). 
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Table 4. Major components in creosotes according to the studies A-G. 
 
Weight-% Compound Formula 
Aa Bb Cc Dd Ee Ff Gg
Aniline C6H7N      0.05f1  
Quinoline C9H7N   1   2.0 f1 0.9 
Isoquinoline C9H7N      0.7 f1  
Indole C8H7N      2 f1  
Carbazole C12H9N  2.4    3.9 f1 0.9 
Methylcarbazoles C13H11N      2 f1  
Benzocarbazoles C16H11N      2.8 f1  
Dibenzocarbazoles C20H13N      3.1 f1  
Acridine C13H9N      2 f1  
Benzoquinoline C13H9N      4 f1 0.8 
Methylbenzoquinoline C14H12N      0.3 f1  
Benzothiophene C8H6S      0.3f2  
Dibenzothiophene C12H8S       0.9 
Indene C90H8       3.3 
Biphenyl C12H10 0.8-1.6 2.1 1-4   0.8 f2 1.3 
Dibenzofurane C12H8O 5.0-7.5 1.1 4-6   3.9 f2 3.5 
Naphthalene C10H8 1.3-3.0 11 13-18   7.6 14.3 
1-Methylnaphthalene C11H10 0.9-1.7  12-17   0.9 f2 2.1 
2-Methylnaphthalene C11H10 1.2-2.8 3.0 12.0   2.1 f2 4.9 
Dimethylnaphthalenes C12H12 2.0-2.3 5.6     2.1 
Acenaphthylene C12H8       0.8 
Acenaphthene C12H10 9.0-14.7 3.1 9.0   8.3 f2 4.1 
Fluorene C13H10 7.3-10.0 3.1 7-9   5.2 f2 4.7 
Methylfluorenes C14H12 2.3-3.0      2.2 
Phenanthrene C14H10 21 12.2 12-16  1-3.3 16.9 f2 12.7 
Methylphenanthrenes C15H12 3.0      2.0 
Anthracene C14H10 2.0  2-7  0.4-1.2 8.2 f2 5.6 
Methylanthracenes C15H12 4.0 5.9      
Fluoranthene C16H10 7.6-10.0 3.4 2-3 0.5-0.9 0.2-2.2 7.5 f2 6.0 
Pyrene C16H10 7.0-8.5 2.2 1-5  0.1-1.5 5.3 f2 5.0 
Methylpyrenes C17H12       1.9 
Benzofluorenes C17H12 1.0-2.0 3.4     3.0 
Benzo(a)anthracene C18H12    0.2-0.3    
Benzo(k)fluoranthene C20H12     0.16-0.3   
Dibenz(ah)anthracene C22H14    0.01-0.04    
Chrysene C18H12 2.6-3.0 2.2 1h  0.9h  1.5 h
Benzo(a)pyrene C20H12    0.04-0.06 0.02-0.16 0.43 f2  
a reference 23, a creosote, the American Wood-Preservers’ Association standard P1 
b reference 24, 6 creosotes, 4 unspecified and 2 fulfilled the U.S. Federal specifications I and III 
c reference 25, 26, creosote used in the impregnation of railway ties 
d reference 27, 3 creosote samples, not specified 
e reference 28, 3 creosote, all fulfilled the British standard BS144/73/2 
f reference 21, f1 concentration in nitrogen compound fraction, f2 concentration in PAH fraction 
g reference 29, typical wood preservative creosote 
h includes triphenylene
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3. Occupational Exposure to Creosote and Its Compounds  
3.1. Exposed workers 
Occupational exposure to creosote may occur at tar distillation plants, during transporting of creosote 
oil, at impregnation plants, and during subsequent handling and use of impregnated timber. The 
handling includes transportation and loading of impregnated wood, e.g. at ports, assembling of rail 
roadway switches and ties, installing and repairing of impregnated poles, piles and other installations. 
Occupational exposure may also occur during the manual application of creosote, e.g. in the treating 
fences and sheds. The use of creosote paint was ceased in Finland at the end of 1990s (the Finnish Wood 
Preserving Association). It is also possible that workers handling contaminated soil can be exposed. 
 
Creosote impregnation began in Finland in 1904 when The State Railways started the impregnation of 
railway ties at two sites (Ruukki and Mikkeli) using the full cell process. The plants operated only 
during the summer seasons, and employed 20-30 persons. The empty-cell process was commissioned in 
1910 (VR Group Ltd). 
 
Creosote is not distilled in Finland. The number of impregnation plants was seven at the end of the 
1980s, at the end of the 1990s there were four creosote impregnation plants in Finland. The number of 
workers directly exposed in Finnish impregnation plants is usually 3-6/shift, and the number of other 
workers such as supervisors, cleaners, and technicians controlling the quality of the impregnated timber 
can amount to 3-6 persons/plant. At the end of the 1980s, the number of workers in the impregnation 
plants was 60-80, the number of workers in the preparation, installation and repairing of railway ties was 
about 2000, the number of thermite and arch welders 130, and the number of workers handling other 
treated wood 250 30. At the end of the 1990s, the impregnation plants employed 30-40 workers, and 
altogether a few hundred workers handled creosote-impregnated wood in Finland. Occasionally a few 
stevedores load impregnated wood onto ship. 
 
Potential occupational exposure to coal tar or coal tar pitch has occurred in Finland e.g. in the following 
industries: water-proofing of buildings (especially basements), roofing (before 1973), manufacture and 
use of roof felts (before 1970), gasification of coal (before 1975), production and use of road-surfacing 
mixes (before 1973), iron foundries (before 1985), production and use of coal tar paints (still today), 
impregnation and use of creosote-impregnated wood (after 1904), coking of coal (after 1987). Potential 
exposure  has also occurred or is still occurring in the maintenance, renovation or subsequent use of the 
materials containing coal tar or pitch, e.g. in the handling of wastes and contaminated soil, and in the 
renovation of old buildings in which coal tar or pitch have been used as a water-proofing layer. 
 
3.2. Limit values 
3.2.1. Occupational exposure limit values 
Finnish occupational exposure limit (OEL) values for the main compounds identified in creosote oils are 
listed in Table 5. The values adopted by other Scandinavian countries and the American Conference of 
Governmental Industrial Hygienists (ACGIH) are also quoted, if they differ from the corresponding 
Finnish values. 
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The first attempt to derive an OEL for PAHs was carried out by the ACGIH in 1967, when it proposed a 
Threshold Limit Value (TLV®) of 0.2 mg/m3 for coal tar pitch volatiles (CTPV). Since then, this limit 
value has been widely used since then to control exposure to emissions from coal tar, coal tar pitch, and 
even to emissions from bitumen products 2. The method is, however, unspecific, and in addition to 
particulate PAHs, it measures any substances soluble in cyclohexane or benzene. The concentration of 
PAHs may be underestimated or overestimated, depending on the content and composition of PAHs in 
the mixture.  
 
Table 5. Occupational exposure limit (OEL) values for major compounds identified in creosotes 
 
Agent OEL8h
(mg/m3) 
OEL15 min 
(mg/m3) 
Notation Country 
Toluene 190 380 Skin Finland a
Xylenes 440 660 Skin Finland a
Indene 48 96  Finland a
Diphenyl 1.3 3.8  Finland a
Phenol 20 39 Skin Finland a
Cresols 22 45 Skin Finland a
Naphthalene 53 
53 
110 
80 
 
Skin 
Finland a
USA b
BaP 0.01 
0.002 
 
0.02 
 
Skin, carcinogen, effects 
on reproduction 
Finland a
Sweden c
PAH 0.04  Carcinogen Norway d
CTPVe as benzene solubles 0.2  A1f USA b
a STM, HTP-arvot 1998 (in Finnish). Turvallisuustiedote. Vol. 25. Sosiaali- ja terveysministeriö, 
Kemian työsuojeluneuvottelukunta. 1998, Tampere. pp. 50. 
b ACGIH, Threshold Limit Values  for Chemical Substances and Physical Agents; Biological  
Exposure Indices. 2000, Cincinnati, OH: American Conference of Governmental Industrial 
Hygienists. 
c Arbetarskyddsstyrelsen, Hygieniska gränsvärden (in Swedish). Arbetarskyddsstyrelsens 
författningssamling, AFS. Vol. 2. 1996, Stockholm. 
d Arbeidstilsynet, Veiledning om administrative normer for forurensning i arbeidsatmostfære (in 
Norwegian). Direktoratet for arbeidstilsynet. Vol. AT-361. 1996, Oslo.  
e  CTPV= coal tar pitch volatiles  
f  Notation A1 = Confirmed human carcinogen by ACGIH 
 
CTPV fractions of coal tar fumes monitored in aluminium plants and in road paving with mixes 
containing coal tar have been found to contain 20 - 40% identified PAHs 31, 32. Based on these results, 
concentrations of 0.040 to 0.080 mg/m3 of identified PAHs correspond to 0.2 mg/m3 of CTPV fraction. 
Norway has adopted an OEL of 0.040 mg/m3 for PAHs, but PAHs, which are included in the OEL, are 
not defined. The ACGIH has not given TLVs® for carcinogenic PAH compounds such as BaP, 
benzo(a)anthracene, benzo(b)fluoranthene, but has assigned them with the notation A2, implying 
suspicion of  human carcinogenicity. Swedish authorities have used the skin notation for BaP and 
ACGIH for naphthalene (Table 5). 
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3.2.2. Biological indices 
Urinary metabolites of naphthalene and pyrene, 1-hydroxynaphthalene (1-OHN) and 1-hydroxypyrene 
(1-OHP), have been used to describe exposure to PAHs (Table 7). However, there are no biological 
action levels for urinary 1-OHN and 1-OHP in Finland. The Finnish reference values of urinary 1-OHN 
and 1-OHP concentrations for non-occupationally exposed persons are 7.7 and 0.23 µmol/mol 
creatinine, respectively 33.   
 
Biological exposure indices for 1-OHP in urine are proposed in the literature. These exposure indices 
are based on the relationship between the concentration of CTPV or BaP in air and 1-OHP in urine. The 
1-OHP concentration in urine at the end of the work shift  that has corresponded to a 5 µg/m3 airborne 
BaP concentrations, has been 6.7 µmol/mol creatinine in coke oven workers 34. Correspondingly, the 
concentration that has corresponded to 0.2 mg/m3 as CTPV is 1.8 µmol/mol creatinine. Based on these 
relationships, Jongeneelen 34 proposed a biological exposure index of 2.3 µmol/mol creatinine for coke 
oven workers, and he estimated it to be equal to a relative risk of lung cancer of approximately 1.3. In 
another study among coke oven workers, a proposed limit value of 3.2 µmol/mol creatinine was equal to 
an airborne concentration of 2 µg/m3 BaP 6. In the aluminium industry, a maximal weekly increase of 
4.3 µmol/mol creatinine was suggested as a limit value 35. Due to the great variation in the profile of 
airborne PAHs, some authors have proposed a correction factor using the pyrene/BaP ratio, in situations 
where the PAH profile differs from those in coking and aluminium plants 36, 37. 
 
3.3. Exposure assessment 
3.3.1. Airborne impurities 
Occupational exposure to coal tar or coal tar pitch has been monitored by measuring the concentration 
of CTPV gravimetrically either as a benzene or cyclohexane soluble fraction. Fumes can be collected on 
a glass fibre filter, on the combination of a glass fibre filter and a silver filter, or on a polytetra-
fluoroethylene (PTFE) filter 38, 39. The method has also been applied to creosote fumes 16, 40. However, 
poor accuracy and precision, e.g., weight loss of glass fibre filters and high field blanks at the exposure 
limit have been noted with the CTPV method 32, 41, 42. The precision of the method was very poor when 
tested with creosote fumes 16. This method does not identify any constituents of airborne particles, nor 
does it measure vapours. The CTPV method has been widely used as a measure of PAH exposure, but it 
has serious limitations for determining the level of airborne PAHs. The concentration of airborne 
particulate PAHs is currently monitored by sampling them on glass fibre or PTFE filters, and by 
analysing with a HPLC/fluorescence detector or with GC to determine the concentrations of individual 
PAHs 26, 43. 
 
The concentration of creosote vapours has been measured by sampling them on activated charcoal or 
Amberlite XAD-2, which have been analysed by GC equipped with a flame ionising detector (FID) or 
by HPLC equipped with a fluorescence detector 26, 44. Generally, XAD-2 or other polymer sorbents are 
used in the sampling of vaporous PAHs, since desorption of these compounds from activated charcoal is 
poor4. 
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3.3.2. Skin contamination 
Dermal exposure occurs normally by one of three pathways: (i) immersion (direct contact with a liquid 
or solid chemical substance); (ii) deposition of aerosol or uptake of vapour through the skin; or (iii) 
surface contact (transfer from contaminated surfaces). Occupational respiratory exposure is expressed as 
the air concentration of an agent (e.g. µg/m3). Similarly, dermal exposure can be defined with the 
amount of material reaching the skin, and referred to as skin loading (e.g. µg/cm2). The skin loading rate 
has the same unit (e.g. µg/cm2/h) as the skin penetrating rate (flux). This term describes the steady state 
movement of chemicals through the skin. Flux varies across the anatomical region 45; the thickness of 
the outer layer of the epidermis, the so-called horny layer or scrotum corneum varies considerably. The 
thinnest layer is 0.01 mm (e.g. eyelids and scrotum), while the thickest is 1 mm (e.g. sole).  
 
Dermal exposure is still rather seldom measured in occupational environments. No standard methods 
exist today for this purpose 46, and there are no limit values to interpret the results. Because 
contamination of the skin can arise in many ways, the method to be chosen should depend on the route 
of transport of a contaminant. Direct methods for measuring skin contamination include the use of 
surrogate skin methods (exposure pads, coveralls, gloves, etc.), chemical removal methods (wipes and 
liquid rinses) and fluorescent tracer techniques 45. 
 
Three methods to estimate skin contamination to PAH were tested in a Dutch wood impregnation plant. 
The skin wipe technique (chemical removal method), and coverall and polypropylene pads (surrogate 
skin methods) were compared. Pyrene was used as a marker compound. The results of the wipe method 
were two times higher than those of the pads, and the results of coverall analysis were five times higher 
than those of the pads. There was high variability in pad contamination between the workers and 
between the skin sites within a worker 47. The estimation of total body skin contamination is based on 
the assumption that each pad or wiped area represents the total site where the pad is pasted. The coverall 
method and wipe technique represent a larger body area than the pads. In addition, the lipophility of 
pads is different from that of the skin.  
 
3.3.3. Biomarkers of exposure and effect 
A metabolite of a PAH component, 1-OHP, has been used to describe exposure of creosote workers to 
PAHs 48-50. Metabolites of other PAHs measured in other workers include 1-OHN 51-53, hydroxy-
chrysenes 54, hydroxyphenanthrenes 55, 56, and hydroxybenzo(a)pyrenes 57, 58. The concentration of 
hydroxybenzo(a)pyrenes has been determined in the urine of experimental animals after oral 
administration, and in the urine of patients after dermal application of coal tar ointments 59, 60. But 
current methods, however, are not sensitive enough to determine small quantities of this metabolite in 
the urine of occupationally exposed workers 57, 58. Because of the ubiquitous nature of PAHs in the 
environment, the detection of PAH metabolites in the urine is not specific for creosote. 
 
Naphthalene is one of the major compounds of total PAHs in urban air and in some occupational 
environments 3, 61, 62, although it is rarely monitored with other PAHs. The content of naphthalene in 
food appears to be low; thus urinary hydroxy naphthalenes can be used as markers for airborne 
naphthalene for the general population 63. Urinary 1-OHN has been analysed by high-resolution gas 
chromatography (HRGC)/electron capture detector (EC) as a pentafluorobenzylbromide-derivative 63, 64 
or by the HPLC/fluorescence method 53. Both acid and enzymatic hydrolysis of conjugated 1-OHN have 
been used. The use of mass spectrometry (MS) with HRGC yielded a detection limit low enough to 
separate non-smokers from smokers 63. 
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1-OHP was reported to be a major metabolite of pyrene in pig urine, using HPLC with fluorescence 
detection and HRGC/MS confirmation 65. Jongeneelen and his co-workers subsequently performed a 
series of studies evaluating the excretion of 1-OHP in the urine of both rodents and humans as a 
biomarker of exposure to PAHs 48, 66-69. Since then, this method or its modifications have been used 
widely. The method is useful because pyrene is present in all PAH mixtures, and in certain 
environments the pyrene content in the total PAHs is fairly constant 70-72. In the general population, the 
intake of pyrene derives from the ambient air, from tobacco smoke, and from the diet, the latter two 
being the most significant sources 3. 
 
The method of determination consists of enzymatic hydrolysis of conjugated 1-OHP in urine samples, 
followed by solid-phase extraction and HPLC separation with fluorescence detection 66. Heat and strong 
acid hydrolysis did not yield a good recovery of 1-OHP 65. Acid hydrolysis has been used in animal 
studies, where the excretion rate of 1-OHP in urine was reported to be low, below1% by different 
routes73. Besides HPLC separation with fluorescence detection, GC/MS has been used for 1-OHP 58, 74, 
and HPLC/fluorescence detector in combination with synchronous fluorescence spectroscopy for 1-
OHP-glucuronide conjugates 75. 
 
Biomarkers serve as an indicator of genotoxic effects of creosote. They are used to determine 
mutagenicity in the urine of wood-preserving workers 76, and to identify DNA adducts in the skin and 
blood of psoriatic patients 60,  and in the tissues of experimental animals exposed to creosote 77, 78. 
 
3.4. Exposure level 
3.4.1. Air 
Only few studies have described the exposures of creosote workers. The concentrations of airborne 
impurities such as CTPV and PAHs have been measured in the USA, Sweden and Finland in 
impregnation plants in the 1970s and '80s (Table 6). Urinary concentrations of 1-OHP have been 
monitored among Dutch and Canadian impregnation plant workers (Table 7) 43, 48, 50, 67. Besides the 
unpublished Finnish data from the 1980s, no results are available on the exposure level in the handling 
of impregnated wood. 
 
The comparison of respiratory exposure levels of creosote workers between different plants and 
countries is difficult due to the different measurement methods, different compounds measured, and 
partly due to the uncertainty of the methods, e.g. the CTPV method. The compounds that can be used for 
the comparison of exposure levels  are naphthalene and BaP. So far these results are scanty, however. 
The measured, maximum concentration of naphthalene in impregnation plants in the USA 44 has been 
10-fold compared to that in Swedish plants at the beginning of the 1980s 25, 26, 43. In the early 1980s 
concentrations of BaP have been  reported to be below 0.3 µg/m3 in pressure impregnation plants in 
USA 44, <0.02-0.05 µg/m3 in Swedish plants 25, 26, and <0.01-0.07 µg/m3 in Finnish plants 79. The BaP 
concentration in air has been 0.8 µg/m3 in a German plant where thermal dip treatment was applied 80.  
 
Naphthalene, fluorene, and phenanthrene have been  the most abundant compounds appearing mainly as 
vapours (Table 6). The sum concentration of particulate PAHs has ranged from <0.1 to 31 µg/m3, and 
the fluorene, phenanthrene and anthracene have been the major PAH compounds in particles 25, 26, 43.  
In the handling of impregnated wood, measurements have been carried out during assembling of railway 
switch elements indoors, and during manual metal arch (MMA) welding of rails outdoors 81. The 
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concentration of naphthalene has ranged from 1-8.5 mg/m3 and that of BaP from 0.08-0.98 µg/m3 in the 
assembly hall and that of BaP at the breathing zone of MMA welders from <0.01-0.63 µg/m3 (Table 6). 
 
In comparison, the mean concentrations of BaP at the end of the 1970s have been reported to be 5.1 
µg/m3 (range 0.2-72 µg/m3), when coal tar pitch has been used as a moulding additive in Finnish iron 
foundries, and 0.08 µg/m3 (range 0.01-0.10 µg/m3) when coal powder has been used 82. When the 
Finnish coke plant started its operation in 1987, the mean concentration of BaP was 2.5 µg/m3 (range 
0.02-19 µg/m3), and in 1994 after technical improvements in the process 0.16 µg/m3 (range 0.01-1.53 
µg/m3) 62, 83. 
 
3.4.2. Skin 
The dermal pyrene contamination of Dutch creosote workers  not wearing coveralls has been on average 
500 (47-1510) µg/day, and that of the workers wearing coveralls 160 µg/day. The use of coveralls has 
reduced the dermal contamination and the concentration of urinary 1-OHP 43. Among Dutch road pavers 
who have used mixtures containing coal tar the median pyrene contamination of the skin has been 
117 µg/day 49. 
 
The dermal pyrene contamination has measured to be 395 µg/day (6-192 ng/cm2) among workers in a 
Dutch aluminium plant 5, 70 µg/day in a Dutch coke oven plant 6, and 1.3-2.0 ng/ cm2 in an Estonian 
coke oven plant 84. Dermal exposure to BaP has been in the range of 2-34 ng/cm2 in a Dutch aluminium 
plant 5 and 0.7-2.0 ng/cm2 in an Estonian coke oven plant 84. In the Dutch coke oven plant, the use of 
laundered working clothes, a new pair of gloves before each 8-hour work shift, and washing the hands 
and face before each break have reduced the urinary 1-OHP concentrations by 37% on average 85. 
 
Van Rooij and others 6, 43, 47 have concluded that the total average dermal pyrene contamination of the 
workers in the above industries is 9-times higher than the results measured with pads. The total pyrene 
dermal exposures have estimated to be 3.1 (0.4-13.6) mg/day, 3.9 (0.8-16.8) mg/day and 0.6 (0.2-1.5) 
mg/day for the workers from a creosote wood-preserving plant, from an aluminium plant, and from a 
coke plant, respectively. 
 
3.4.3. Urinary metabolite concentrations 
Urinary levels of 1-OHP have been measured in several work environments. There are only a few 
studies describing the urinary concentration of 1-OHN. Table 7 summarises the published results for 
workers, and Table 8 for the controls. The urine of concurrent controls has been examined in most 
studies. Unexposed workers at the same plant, such as administrative workers, have had slightly higher 
1-OHP concentrations than those of the general population 35, 71, 72, 86. 
 
The 1-OHN and 1-OHP concentrations have been reported in different units, as is, or as corrected either 
for the specific gravity or creatinine. For the sake of comparison, the results have been converted to 
µmol/mol creatinine by assuming that the mean urinary creatinine concentration is 13 mmol/L (1.47 
g/L) yielding the following conversion factors 3: 
 
1-OHN: 1µmol/mol creatinine = 1.27 µg/g creatinine = 0.013 µmol/L  
1-OHP: 1µmol/mol creatinine = 1.93 µg/g creatinine = 0.013 µmol/L  
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Table 6. The concentrations of identified vaporous and particulate compounds in air in creosote impregnation plants and in the handling of treated wood. 
 
Impregnationa Impregn.b Impregn.c Impregn.d Impregn.e Impregnationf Assembling of rails WeldinggCompound 
 
 Vapours mg/m3
Particles 
µg/m3
Particles 
µg/m3
Vapours 
mg/m3
Particles 
µg/m3
Particles 
µg/m3
Vapours 
mg/m3
Particles
µg/m3
Vapours 
mg/m3
Particles 
µg/m3
Particles 
µg/m3
Diphenyl 0.05-0.34           
Naphthalene          
        
         
         
        
        
         
        
        
         
           
           
           
         
       
          
           
           
         
0.1-3.2 <0.5-2.1
 
0.6-42 1-8.5
 
 
Methyl naphthalenes
 
 0.3-1.1 0.2-4.1
 Fluorene 0.01-0.08
 
 <0.1-4.1
 Acenaphthene 0.07-1.6
 
 
Phenanthrene 0.01-0.16 <0.1-16.0 0.08-7.6 <0.01-2.8
Anthracene ≤ 0.01 
 
<0.05-4.7 <0.01-0.3 <0.01
Fluoranthene <0.03-1.7
 
0.15-8.9 <0.01-2.8
Pyrene 0.4-0.6
 
 0.46-0.6
 
0.11-7.7 <0.01-1.9 
Chrysene/triphenylene
 
<0.05-0.8
 
0.01-3.5 <0.01-0.3
Benzo(a)fluorene 0.6 <0.01-0.8 <0.01
Benzo(b)fluorene <0.01-0.8 <0.01
Benz(a)anthracene 0.4 <0.01-2.9 <0.01-1.0
Benzo(b/j)fluoranthene 0.19
 
<0.01-1.0 <0.01
Benzo(k)fluoranthene
 
 <0.01-0.7 <0.01
Benzo(a)pyrene <0.02-
0.05 
 
<0.3h <0.01-0.07 <0.01-1.0 <0.01-0.6
Benzo(e)pyrene <0.01-0.6 <0.01-0.2
Dibenzo(ah)anthracene <0.03-0.3 <0.01
Benzo(ghi)perylene
 
<0.03-0.2 <0.01
PAHs 0.4-4.9 <1.3-31 <0.5-36.3 <0.01-10
≥4 aromatic ring PAHs 
 
 <0.1-2.1         
     
       
<0.2-19.5
 
 <0.2-4.7
 CTPV 40-400 70 (0.01-
0.6) 
 10-1300 20-400 
No. of samples 9 6 10 20 
169 
12 8 20 20 5 4 3
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a Sweden 1983, reference 25, 26; b USA 1977, reference 40; c USA 1981, reference 44; d USA 1983; reference 16;  
e Finland 1980, reference 79, f The Netherlands 1993, reference 43; g Finland 1983, reference 81; h Detection limit 
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The highest reported urinary 1-OHP excretion has been found in the urine of workers in a creosote 
impregnation plant. The concentrations of urinary 1-OHP have been 50-85 µmol/mol creatinine among 
Dutch impregnation plant workers in the 1980s 49. The urinary 1-OHP concentrations have been 
reported to be significantly lower in the 1990s: on average 1.6 µmol/mol creatinine in two Canadian 
plants 50, and 9.9 µmol/mol creatinine among Finnish impregnation plant workers 87. Other workplaces 
where high exposures have been detected include coal tar distillation plants, a coal liquefaction plant, 
coke plants, graphite electrode plants and aluminium plants. The mean concentrations of 1-OHP in urine 
have been in the range of 0.2-30 µmol/mol creatinine in these industries. Road pavers laying road-
surfacing mixtures that contain coal tar have had a mean 1-OHP urinary level of 1.8-2.2 µmol/mol 
creatinine. On the other hand, the manufacture and handling of  mineral-oil-derived bitumen did not 
result in a significant increase in urinary excretion of 1-OHP (Table 7). 
 
The highest 1-OHN excretions, 550-3400 µmol/mol creatinine, have been reported in the urine of 
workers from distillation plants of coal tar and naphthalene oil 51, 52. The concentrations of 1-OHN have 
been equal to the concentrations of 1-OHN measured in the urine of psoriatic patients after topical 
treatment with coal tar ointment 88. In an iron foundry, the concentrations of urinary 1-OHN have been 
at the level of the controls 89, 90. 
 
3.4.4. Genotoxic biomarkers 
Deoxyribonucleic acid (DNA) adducts of PAHs have been detected ( 32P-postlabelling) in the skin and 
lungs of mice after topical application of creosote on the skin 77, 78. After topical application of coal tar 
ointment for one week on the skin of psoriatic patients, increased levels of aromatic DNA adducts (32P-
postlabelling) were observed in the skin and white blood cells 60. The DNA adduct levels in the skin 
were higher than those observed in the white blood cells. The excretion of 3-hydroxybenzo(a)pyrene, 
but not that of 1-OHP, correlated with the levels of DNA adducts in the skin. However, the sensitivity of 
DNA adducts in the white blood cells, as a measure of exposure to PAHs, was limited. 
 
The mutagenicity of urine from persons exposed to PAHs has been assayed in a number of studies by 
Ames’ test 3. No increase in mutagenic activity was found in most studies of workers exposed to PAHs. 
Ames’ test does not appear to be sensitive enough to detect the presence of urinary mutagens due to 
occupational exposure to a low level of PAHs. Animal tests have shown that mutagens appeared in the 
urine of rats after intraperitoneal administration of creosote. Despite these results, no increase in 
mutagenicity has been detected in the urine of creosote workers in relation to their work 76, 91. No 
increase of urinary mutagenicity was observed in the urine of coal tar distillation plant workers, either 66. 
Heavy exposure of psoriatic patients to coal tar preparations has resulted in mutagenic urine 92, 93. 
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Table 7. The concentrations of three PAHs in air (µg/m3) and of two metabolites in urine (µmol/mol 
creatinine). 
 
 Naphthalene Pyrene BaP 1-OHN 1-OHP N Ref. 
Wood impregnation 
with creosote 
       
The Netherlands     0.5-21 
0.6-82 
60 
25 
48 
34
Canada  <0.01-0.12   1.6 (0.18-10.5)g 19 50
Finland 
 1992-99(morning) 
 1996-98(end of shift) 
    
92 (<3-720)a
 
 
 
7.9 (1.1-34)a
 
35 
31 
 
94 
87
Distillation of 
naphthalene oil 
 
 
      
Poland  
870 
  3430 
730 
 75 
33 
51 
52
Distillation of coal 
tar 
       
The Netherlands  5 (1.4-8.5)g   6 (3.7-11.8)g 12 66
Poland 770   690  51 52
Coal liquefaction        
United Kingdom 
  1991 
  1993 
  
0.6-2.8g
- 
   
8.6 (0.4-73)g
7.1 (0.6-20)g
 
10 
24 
 
95
Coke plant        
Belgium 
  non-smokers 
  smokers 
  
0.01-88.3 
0.01-88.3 
 
0.002-32
0.002-32 
  
1.2g-5.6g
0.8g-6.1g
 
7 
9 
 
71
China 
  top side 
  top side, coke side 
     
20.6a±14.0 
8.2a±1.2 
 
27 
31 
 
72
Estonia 
all workers 
     
6.0a(0.2-69.5) 
 
49 
 
84
Finland 
 1988, shift workers 
 1994, shift workers 
 
83-206 
 
3.5a
0.6a
 
2.5a(0.01-19)
0.3a
 
 
0.06a
 
0.62a (0.01-5.1) 
0.16a (0.01-
2.35) 
 
156 
159
 
62, 83
Italy 
  non-smokers 
  smokers 
     
0.94a(0.04-3.93) 
1.53a(0.14-1.19) 
 
39 
52 
 
93
The Netherlands 
  top side 
  other work 
     
3.3a(0.8-7.5)
1.9a(0.6-4.1) 
 
19 
25 
 
96
Norway   0.72a-1.5a  1.11a-5.53a 67 97
Poland 
  old technology 
  modern technology 
 
 
0.1-10 
  
 
 
2980g
730g
 
 
 
57 
66 
 
51
Sweden 
  before renovation 
  after renovation 
   
4g (0.9-37) 
0.7g (0.2-6.8)
  
4.7g (0.3-30) 
1.3g (0.5-5.7) 
 
10 
10 
 
86
USA 
handling of sludge 
 1    
1.7a (0.24-4.9) 
 
18 
 
98
Steel plant        
China     1.8a±0.7 12 72
3. Occupational Exposure to Creosote and Its Compounds 
 
 
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 120  31   
Table 7. (continued) 
 Naphthalene Pyrene BaP 1-OHN 1-OHP N Ref. 
Graphite electrode 
plant 
       
Belgium 
  non-smokers 
  smokers 
  
8.8g-27.3g
0.04g-3.52g
 
0.03g-6.2g 
0.03g-6.2g
  
0.6g-4.1g
0.5g-4.9g
 
36 
44 
 
71
Germany 
  baking 
  impregnation 
  all workers 
  
4.5a
3.1a
 
 
1.2a
1.1a
 
  
12.1g
11.4g
4.5g
 
30 
9 
67 
 
56
Norway 
non-smokers 
smokers 
 
95a 
95a
 
3.5a 
3.5a
 
0.8a 
0.8a
  
5.69a±1.23 
8.12a±0.76 
 
13 
21 
 
61
Aluminium reduction 
plant 
       
Söderberg-type anodes        
 The Netherlands 
  electrode men 
  potmen 
  
130a
25a
 
47a
2.7a
  
43a 
35a
 
4 
9 
 
35
Sweden 
  potroom workers 
   
2.8g (1.9-36)
  
2.2g (0.5-3.8) 
 
9 
 
86
Prebake-type anodes        
 The Netherlands 
  pot relining 
  bake oven 
  paste plant 
  
60 
1.0 
5.0 
 
1.2 
0.3 
1.3 
  
5.9g (1.9-12.2) 
4.4g (1.0-13) 
3.0g (1.6-7.4) 
 
7 
5 
8 
 
5
  USA 
  anode bake area 
  
2.57a
   
2.7a
 
25 
 
99
Contaminated soil 
France 
     
0.16-5.59 
 
93 
 
100
Shooting target 
factory, France 
  
0.66-5.05 
 
0.037-0.27 
  
1.84-10.9 
 
28 
 
101
Needle coke plant         
The Netherlands 0.23a <0.01 <0.01  2.0a(0.2-13.2) 12 36
Carbon black plant 
United Kingdom 
     
0.33a
 
5 
 
102
Harbour terminal 
non-smokers 
smokers 
     
0.47a±0.21 
0.67a±0.24 
 
3 
4 
 
49, 67
Paving with asphalt        
Finland, bitumen 4-20 0.01-0.2 <0.01  0.51a 32 103
The Netherlands 
 bitumen and coal tar 
     
0.4a-3.2a
 
70 
 
67
 bitumen and coal tar 
   non-smokers 
   smokers 
     
0.53a±0.45 
0.68a±0.30 
 
18 
21 
 
104
Sweden, 
bitumen, non-smokers 
     
0.07g
 
57 
 
86
 
 
 
 
Pirjo Heikkilä: Respiratory and Dermal Exposure to Creosote 
 
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 120 32
 
Table 7.  (continued) 
                 Naphthalene Pyrene BaP 1-OHN 1-OHP N Ref
. 
Handling of petroleum 
coke 
The Netherlands 
  non-smokers 
  smokers 
     
 
 
0.24g-0.79g
0.54g-0.90g
 
 
 
36 
40
 
 
 
68
Iron foundry        
Denmark 
  non-smokers 
  smokers 
 
9.7a 
9.7a
 
0.01a 
0.01a
 
0.02a 
0.02a
  
0.022g
0.027g
 
25 
45
 
105
Fire-fighters        
Denmark 
  non-smokers 
  smokers 
     
0.09a
0.20a
 
8 
5 
 
106
The Netherlands 
  non-smokers 
  smokers 
  
 
 
0.029-0.16a
  
0.55a
0.83a
 
13 
20
 
107
Topical treatment of 
patients with coal tar 
       
     13-810 16 92
 118 mg/d 14.3 mg/d  600-2600 60-100 2 88
  67 mg   7.8-260 2 48
N= Number of urine samples 
a  Arithmetic mean 
g  Geometric mean or median 
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Table 8. 1-Hydroxypyrene (1-OHP) and hydroxy naphthalene (1-OHN) mean concentrations (µmol/mol 
creatinine) in non-occupationally exposed healthy adults. 
 
Controls/referents 1-OHN 1-OHP No. of persons Reference 
Belgium 
Coke and aluminium plants workers 
   non-smokers 
   smokers 
  
 
0.08g
0.17g
 
 
9 
9 
 
 
71
Canada 
Office workers in other plants 
  non-smokers 
  smokers 
  
0.07g
0.12g
 
95 
45 
 
108
China  
Residents of large cities 
  
0.8a-1.3a
 
45 
 
72
Denmark 
Office workers, another plant 
Workers, other plants 
Reference values for non-exposed 
 
 
2g
5.7 
 
0.005g
0.005g
0.053 
 
68 
46 
236, 121 
 
105 
90 
109
Finland 
Office workers, coke plant 
Reference values for non- exposed 
 
 
7.7 
 
0.14a
0.23 
  
62 
33
France, Workers, another plant 
  non-smokers 
  smokers 
  
0.02g
0.04g
 
17 
11 
 
100
Japan,  General population 
   non-smokers 
   smokers 
 
1.4g
3.8g
  
34 
38 
 
63
The Netherlands,      
   Unspecified group 
  non-smokers 
  smokers 
 0.26g
0.29g
52 
38 
 
67
   Workers, other plants 
  non-smokers 
  smokers 
  
0.17g
0.51g
 
14 
28 
 
96
Norway, Workers, other plants 
  non-smokers 
  smokers 
  
0.06a
0.18a
 
16 
10 
 
61
Poland 
Unspecified group 
 
80g
  
24 
 
51
Turkey, University staff 
  non-smokers 
  smokers 
  
0.01-0.26g
0.22-0.54g
 
16 
14 
 
104, 110
Sweden 
Office workers, coke oven 
  before renovation 
  after renovation 
Road construction workers 
  
 
1.9g
0.09g
0.04g
 
 
8 
8 
34 
 
 
86
USA  
Unspecified group 
  non-smokers 
  smokers 
  
0.27a
0.77a
 
10 
9 
 
99
a  Arithmetic mean 
g  Geometric mean or median
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4. Health Effects of Creosote and Major Components 
As described earlier (section 2.3.2.) the composition of creosotes varies, depending on many factors, and 
thus the ranges of toxic compounds are wide. Thus, the health effects of different creosotes may 
accordingly be different. Since the major part (>50%) of creosote is comprised of polycyclic aromatic 
compounds, the uptake, biotransformation and excretion of these compounds are briefly described in the 
following. In addition, the health effects of the main constituents identified in creosotes are described. 
 
4.1. Uptake and biotransformation 
4.1.1. Absorption 
Polycyclic aromatic hydrocarbons: Polycyclic aromatic hydrocarbons are lipophilic compounds and 
can be absorbed via the lungs, the gastrointestinal tract, and the skin 3. The respiratory rate of absorption 
depends on the type of PAH; vaporous compounds will be absorbed more rapidly than PAHs bound on 
particles. 
 
Animal data show that almost complete and rapid absorption occurs following ingestion of naphthalene: 
at 72 h approximately 83% of the given naphthalene was recovered in urine and 8% in faeces of rats 111. 
No published animal data are available on the absorption of naphthalene following inhalation. After 
dermal application of naphthalene to rat skin, about 50% of the dose was excreted in urine within 
12 h 112. 1-OHN has been detected in the urine of workers exposed occupationally to naphthalene 51, 52, 
and in the urine of psoriatic patients who were being topically treated with coal tar ointment 88.  
 
The pulmonary retention of pyrene was on average 61%, and the fraction of percutaneously taken 
pyrene was 22.5% among five volunteers exposed to PAH mixture in an aluminium plant 113. However, 
the pulmonary retention, as measured in the study, is a valid indicator of the uptake only for vapours or 
gases, but not for particles, because inhaled particles are transported to the airways by a different 
mechanism from vapours 114. Pyrene appears both as vapour and bound on particles in air. PAHs on 
particles are deposited on the airways in according to the mechanism of airborne particles. The clearance 
of particulate PAHs follows a biphasic pattern. There is a rapid initial phase during which particles are 
partly cleared by the mucociliary mechanism, which surveys the particles up to the pulmonary tree from 
where they are swallowed, thus entering the organism through the gastrointestinal tract. The  second  
phase has a half-life of several days 114. The deposited PAHs are dissolved and metabolised in the 
lungs 3.   
 
Dermal absorption of several PAHs in coal tars and creosote has been demonstrated in humans. When 
coal tar in petroleum jelly was applied topically, phenanthrene, anthracene, pyrene and fluoranthene 
were detected in the peripheral blood 115. Volunteers treated topically with creosote or pyrene excreted 
1-OHP in urine. In each case, maximal excretion was detected 10-15 h after treatment 74, 116.  
 
Percutaneous penetration of PAHs is affected by several factors such as the matrix, the dose, and skin 
thickness. Dankovic has shown that the dermal half-life of BaP as a pure substance is shorter than when 
it is applied on the skin in a complex coal tar mixture 117. But when BaP is in a volatile organic solvent, 
its dermal half-life is shorter than that of the pure substance 117. These results have been confirmed by 
Sartorelli's study where PAHs in lubricating oil and in acetone were applied on monkey skin in vitro 118.  
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Absorption of 10 PAHs from coal tar was studied in vitro using a blood-perfused pig ear model. The 
results showed that the mean relative cumulative uptake of PAHs varied from 0.01 for indeno(1,2, 3-
cd)pyrene to 12 for phenanthrene, as compared with that of 1 for pyrene 119. The penetration of the 
compounds was followed for about 6 hours. The skin permeability constants, which are in linear relation 
to  the dermal penetration rates, have been measured to be 5.12 x 10-3 cm/h for naphthalene, 1.69 x 10-3 
cm/h for pyrene and 0.15 x 10-3 cm/h for benzo(a)anthracene 120. Studies on the uptake and excretion in 
rats have shown that when 14C-pyrene and BaP were applied on the skin, about 47-52% of the applied 
pyrene 121, and, correspondingly, from 46% 122 to 70% 123 of BaP was recovered in the excretion in six 
days. The order of skin absorption in in vitro dermal absorption tests with BaP has been 96% for rat, 
51% for hairless guinea pig and 23% to 43% for humans 123. When surface disappearance of PAHs was 
measured with a luminoscope, 20 to 56% of a dermally applied dose was absorbed in 6 h from 
exposure 124. The mechanisms of the percutaneous absorption of different PAHs are probably different: 
e.g. BaP is mainly mediated by a biotransformation process 125, whereas pyrene is absorbed primarily by 
a passive diffusion process 126.   
 
The daily pyrene uptakes for the workers from a creosote impregnation plant, an aluminium plant and a 
coke plant have estimated to be  685 µg, 940 µg and 140 µg, respectively 6, 43, 47. The respiratory pyrene 
uptake was assessed to comprise 10% or less from the total pyrene uptake. The large contribution of 
dermal exposure (70%) to the total uptake of PAHs has also been confirmed among coal liquefaction 
workers 37. 
 
Phenols: Phenol is also readily absorbed after inhalation, ingestion and skin contact. Skin absorption 
can be significant in all forms of phenols, but in practice, skin is the main route of exposure as the 
vapour pressure of phenol and cresols is low 127.  
 
4.1.2. Metabolism and excretion 
Polycyclic aromatic hydrocarbons: The metabolism of PAHs to more water-soluble derivatives 
involves complex reaction chains. In the primary step, they are activated to arene oxides by cytochrome 
P450 (CYP)-dependent mono-oxygenases. They may be spontaneously isomerised to phenols or 
converted enzymatically to dihydrodiols 3. In addition to being conjugated, dihydrodiols can undergo 
further oxidative metabolism. Metabolites of PAHs with 2 and 3 rings are preferably excreted in urine, 
while the higher molecular ones are excreted in faeces.  
Various CYP mono-oxygenases take place in the metabolic activation of PAHs deriving from CYP 1, 
CYP 2 and CYP 3 families. The most prominent ones are CYP 1A1 and CYP 1A2. The metabolites 
formed by these two enzymes may be different. CYP 1A2 is prominent in the human liver, and thus 
metabolites of PAH intaken orally can differ from those intaken via the lungs 128, 129. The regiospecific 
oxidation of phenanthrene differs significantly in individual rats and in individual humans, which 
indicates that the mono-oxygenases involved differ from one individual to another 128, 130. 
 
Approximately 83% of orally administered naphthalene is excreted in the urine of rats mainly as 
metabolites, the major urinary metabolites being dihydrohydroxy- and dihydroxynahphthalenes 111. 
When naphthalene has been applied to rat skin, the main metabolites have been 1,2- and 2,7-
dihydroxynaphthalenes 112. In humans, the main metabolites of naphthalene are hydroxynaphthalenes: 
Yang 63 reported that urinary 1-OHN concentrations were on average 1.6 times higher than those of  2-
OHN among male workers not occupationally exposed to PAHs. The ratio of 1-OHN to 2-OHN was 
different among the smokers and non-smokers 63.  
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 1-Hydroxynaphthalene        1,2-Dihydroxynaphthalene                 1-Hydroxypyrene 
 
Figure 1. Structural formulas of some PAHs and of some hydroxymetabolites of naphthalene and 
pyrene.  
 
The findings from the studies on the excretion of pyrene as 1-OHP vary greatly. After intravenous 
injection, 57% of pyrene and its metabolites were excreted in urine and 18% in faeces in rats 131, and the 
fraction excreted as 1-OHP or its metabolites was 4.2%. From orally administered pyrene, 14-43% of 
the dose was estimated to transform to 1-OHP in the urine of volunteers consuming grilled hamburgers 
132. In five volunteers, exposed to PAHs in an aluminium plant, the transformation of pyrene taken up 
into urinary 1-OHP was 29% (13-44%) 113. Van Rooij estimated that the percentage of absorbed pyrene 
excreted as 1-OHP was 13% for non-smokers and 21% for smokers among coke oven workers 6. In two 
human volunteers, the fraction of pyrene excreted in urine as 1-OHP was 2.9-4.5% after ingestion, and 
0.19-0.15% after dermal application 116. Kang and co-workers 133 estimated that 1-4% of inhaled pyrene 
from cigarette smoke was excreted as 1-hydroxypyrene glucuronide in urine.  
 
4.2. Local effects on skin, eyes and respiratory tract 
Creosote: Contamination of skin with coal tar sensitises the skin to ultraviolet light, and skin burns may 
appear 2, 134, 135. Coal tars and creosote contain photodynamic compounds, which can generate radicals in 
the presence of ultraviolet light (wavelength 340-430 nm). In the absence of oxygen, they act as 
photoreducing agents. The main effect is epidermal damage. Typically, the photogenic response 
involves a transient erythema, which appears immediately after exposure and is usually over in 1 or 2 
days. Compounds that are reported to be photogenic include, e.g., acridine, phenanthrene, anthracene, 
pyrene and BaP 3, 136. 
 
Irritation symptoms, pitch warts, skin discoloration and tearing have been reported among creosote 
impregnation workers 40, 137. A case report on a worker engaged in railway maintenance describes toxic 
melanoderma that was probably due to creosote. The symptoms were slate-grey colour of the skin and 
follicular hyperkeratosis on the face, neck and forearms accompanied by loss of appetite, general 
malaise, headache and heart pains 138. Workers handling impregnated railway ties have complained of a 
painful and extensive rash on their forearms and faces; the symptoms normally disappear within a few 
hours after work 139. 
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No cases of occupational skin or other diseases caused by creosote or other coal tar products have been 
notified in the Finnish Register of Occupational Diseases. 
 
Roofers working with coal tar pitch developed burning eyes and conjunctivitis when exposed to 
sunlight, and rabbits developed photophobia and severe keratoconjunctivitis when exposed 
simultaneously to ultraviolet light and coal tar pitch volatiles 134. In a questionnaire study conducted 
among Finnish creosote workers, 21% experienced respiratory tract irritation often and 30% 
occasionally (N=265). Rail welders reported respiratory symptoms more often than impregnation plant 
workers or assemblers 140. 
 
PAHs and other compounds: PAHs have adverse effects after dermal administration, such as 
hyperkeratosis. Anthracene, pyrene and BaP have been shown to be phototoxic. Anthracene and 
naphthalene have been reported to cause mild ocular irritation 3. 
 
Phenol is corrosive and toxic following skin contact. Initially, phenol can cause numbness or slight 
tingling, so that contact may be ignored. However, even minor contact can result in corrosive injury 
with burns, blisters, permanent skin damage and gangrene 127. No reliable human information is 
available on phenols, but animal evidence suggests that vapours or mists would be irritating to the nose, 
throat and lungs 127. 
 
Heterocyclic aromatic nitrogen compounds such as indole, pyridine, and acridine may cause irritation 
and dermatitis (reddening, thickening, itching, swelling and cracking skin) in repeated or prolonged skin 
contact 141. 
 
4.3. Systemic toxicity 
Creosote: Despite the fact that creosote has been used as a wood preservative for over a century, there 
are only few published data on its effects to humans. In addition, many of the studies are rather old and 
do not conform to modern standards with regard to documentation. 
 
Values for the median lethal dose (LD50) indicate that creosote has moderate to low acute toxicity orally 
and dermally (Table 9). 
 
Table 9. Acute toxicity of creosote. 
 
Route and species LD50 (mg/kg) Reference 
Dermal, rat >3100 20
Dermal, rabbit 7.95 g/kg 11
Oral, rat 3870-5430 20
Oral, rat 1700 11
 
In a case report of fatal ingestion of creosote, multi-organ failure (liver, kidney, gastrointestinal tract, 
and heart) was attributed mainly to phenolic compounds 142. Between 1989 and 1991, 250 of 6,478 
home accident cases among children involved pesticides in the United Kingdom 143. Seven per cent (8 
cases) were thought to have been poisoned by creosote. 
 
PAHs and other compounds: Acute haemolytic anaemia due to naphthalene has been described in 
several children and adults who have accidentally eaten mothballs 144. Anaemia has also been observed 
among children who have been in contact with naphthalene in clothing 145. Individuals with reduced 
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glucose-6-phosphate dehydrogenase are more sensitive than others 146. 1- OHN has been proposed to be 
a causative factor 144, 147, 148. Naphthalene has been shown to cause cataract in rabbits after oral 
administration 149. Chronic pneumonia, metaplasia in olfactory epithelium and hyperplasia in respiratory 
epithelium of the nose has been found in mice exposed to 10 and 30 ppm naphthalene for two years 150.  
 
The vapour pressures of phenol and cresols are low; it is thus unlikely that these compounds pose a 
hazard by inhalation unless heated or misted. Inhalation of high concentrations may cause lung oedema. 
But because phenols are easily absorbed through the skin, repeated contact with dilute solutions or even 
brief contact with concentrated solutions can pose a risk to life. Initially, phenol can cause numbness or 
slight tingling, so that contact may be ignored 127. Phenol may cause effects on the central nervous 
system, heart and kidneys, resulting in convulsions, coma, cardiac disorders, respiratory failure and 
collapse. Long-term exposure to phenol may have effects on the liver and kidneys. 
 
Long-term exposure to diphenyl at high concentrations can result in degenerative liver disease and 
central and peripheral nervous system injury. One death attributed to heavy diphenyl exposure has been 
reported. Heavily exposed workers have reported central and peripheral nervous system symptoms, such 
as headache, fatigue, nausea, abdominal pain, numbness in the arms and legs, and tremor 141. 
 
4.4. Genotoxicity 
Creosote: Creosote has been found to be mutagenic in bacteria tests in the presence of metabolic 
activation with supernatant (containing microsomal fraction) of rat liver homogenase induced with 
Arochlor-1254 and centrifuged at 9000g (S9 mix). The addition of epoxide hydratase inhibitor 
substantially enhanced the mutagenic activity of creosote, and it was concluded that the mutagenicity 
was probably caused by PAHs 151. When creosote was fractionated into seven fractions, two of them had 
high mutagenic activity: one contained BaP and the other benz(a)anthracene 152. Spot samples taken 
from contaminated surfaces at several places in a small wood preserving plant were mutagenic in 
bacteria tests with metabolic activation (S9 mix) 76. When creosote was fractionated into chemical 
classes using adsorption column chromatography, the fraction containing nitrogen compounds was more 
mutagenic than creosote itself in the bacteria tests, but the use of metabolic activation was not 
reported 21. 
 
Creosote and coal tar were examined for the presence of volatile mutagens with the so-called “taped 
plate assay”. The application of this method revealed that vapour escaping from creosote and coal tar at 
37 °C was able to revert the Salmonella typhimurium bacteria strains TA98 and TA100 in the presence 
of S9 mix 153. The “volatile mutagenic activity” was connected with the presence of fluoranthene. The 
tested creosote and coal tar contained fluoranthene in concentrations of 5.2 and 2.2%, respectively 154. 
 
PAHs and other compounds: The genotoxic activity of PAHs in short-term tests has been summarised 
in the World Health Organisation's International Programme on Chemical Safety (WHO/IPCS) 3. Only 
three of the 33 PAHs considered, i.e. anthracene, fluorene, and naphthalene, were inactive in all short-
term tests, whereas phenanthrene and pyrene showed inconsistent results in various experiments. 
Naphthalene, pyrene and other PAHs are metabolised to several primary and secondary oxidised 
metabolites and to a variety of conjugates. Many of the metabolites of PAHs have been tested for 
mutagenicity. Genotoxicity tests have shown that not PAHs, but their oxidised metabolites, are 
genotoxic. There are great differences in the carcinogenic activities of the metabolites of PAH. There are 
several proposed mechanisms for PAH carcinogenesis 3. According to current knowledge, PAHs are 
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activated by microsomal enzymes to compounds which have an electrophilic centre that can react with 
DNA, ribonucleic acid and protein. 
 
Some heterocyclic nitrogen compounds identified in creosotes, such as quinoline and many of its 
oxidation products, are mutagenic 155. Several amino-PAHs, such as 2-aminofluorene, and 
aminophenanthrenes but not aminonaphthalenes, have shown mutagenic activity with metabolic 
activation 156, 157. 2-Aminofluorene has also induced DNA damage in human lymphocytes 158. The 
mutagenicity results for diphenylamines are inconsistent 157, 159, 160. Phenols have not been shown to 
display genotoxic activity in short-term tests 127. 
 
4.5. Carcinogenicity 
4.5.1. Animal studies 
In 1985 IARC evaluated that there is sufficient evidence for the carcinogenicity of creosotes in 
experimental animals2. When creosote was applied to the skin of animals, skin carcinomas and 
papillomas developed, but also an increased frequency of lung cancer was detected in mice treated 
topically with creosote 2. 
 
A recent, dermal carcinogenicity study compared two preparations of coal tar oil. The study showed a 
dose-dependent increase of malignant and non-malignant skin tumours after treatment with tar 
containing 300 ppm BaP (Tar 2). The potency of the different creosote doses correlated with the BaP 
contents. Moreover, as compared to the amount of BaP in the creosote products, the tumour-inducing 
potency of Tar 2 was about five times higher than that observed with BaP alone in the positive control 7. 
 
4.5.2. Human studies 
In 1985 IARC evaluated that evidence of the carcinogenicity of creosote in humans was limited 2. The 
cancers found in case reports and old epidemiological studies were skin cancers (in workers exposed to 
coal tar and in skin disease patients using coal tar ointments), scrotal cancers (creosote-exposed 
brickmakers), lung cancers (roofers) and bladder cancers (tar distillers).  
 
Recent (published after the IARC evaluation) epidemiological studies that combine creosote exposure 
with elevated cancer mortality or incidence are summarised.  
 
In a case-control study on the incidence of multiple myeloma among live cases (131 cases) in 1981-83 
in Sweden, a significantly elevated risk was found among workers exposed to creosote (Mantel-
Haenszel rate ratio 4.7, 95% confidence interval, CI=12-18.0) 161. Creosote workers included, e.g. 
electrical linemen. 
 
Occupational exposure to creosote was found to be a risk factor for both Hodgkin’s disease (odds ratio, 
OR=10.7) and for non-Hodgkin lymphomas (OR=9.4)162. The workers classified as exposed to creosote 
were not described. 
 
Cancer incidence was studied among 922 creosote-exposed impregnators at 13 plants in Sweden and 
Norway. The subjects had been impregnating wood (e.g. railroad cross ties and telegraph poles), but no 
data on individual exposures were available. The study population was restricted to men employed 
during 1950-1975. The total cancer incidence was somewhat lower than expected, 129 cases versus 137 
expected (standardised incidence ratio, SIR= 0.94). Increased risk was observed for lip cancer 
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(SIR=2.50, 95% CI= 0.81-5.83), skin cancer (SIR=2.37, 95% CI 1.08-4.50), and malignant lymphoma 
(SIR=1.9, 95% CI=0.83-3.78). Exposure to sunlight may have contributed to the risk of lip and skin 
cancer 163. 
 
In a population-based cohort study among Finns of working age, cancer incidence was followed from 
1971 to 1985 by occupation and social class. A significantly elevated risk of lip cancer was observed in 
round-timber workers (SIR=3.06, 95% CI=0.99-7.13) and timber workers (SIR=2.15, 95% CI=1.29-
3.35), and an elevated risk of non-melanoma skin cancer in round-timber workers (SIR=4.64, 95% 
CI=1.51-10.8) 164. Impregnation workers, of whom most handled impregnation agents other than 
creosote were classified as timber workers. Workers handling preserved timber belong to two job 
classes: timber and round-timber workers. The risk of non-Hodgkin lymphoma was 1.66 (95% CI=1.02-
2.57) among road and railway construction workers. 
 
In a case-control study of men aged 35 - 70 years, and living in the Montreal area, Canada, the incidence 
(1979-1985) of all cancers was studied from about 300 exposures 165. The number of eligible cancer 
cases was 4576 in the study period. Men exposed to creosote were in occupations such as railwaymen, 
trackmen, roofers, and power linemen. They had an elevated risk of stomach cancer (OR=2.4, 90% 
CI=0.9-6.0) and bladder cancer (OR=2.6, 90% CI=1.0-6.6). The prevalence of creosote exposure was 
1% of the lifetime exposure in the study population. 
 
A case-control survey nested in a cohort of male employees (1978-1989) was undertaken in the French 
national electricity and gas company. During this period, 310 cases of lung cancer were identified. 
Occupational exposure to 21 chemical agents was assessed for each subject.. The analysis showed an 
increased lung cancer risk linked with exposure to crystalline silica (highest exposure class: OR=2.27; 
95% CI=1.10-4.68) and creosotes (highest exposure level: OR=2.14; 95% CI=1.06-4.31), with 
significant dose-response relationships for both exposures 166. 
 
4.6. Reproductive toxicity 
Creosote: Investigations with pregnant swine indicated that direct contact with lumber freshly treated 
with creosote resulted in extensive mortality in the new-born pigs 167. There are two studies on the 
teratogenicity of creosote 168, 169. These studies do not, however, fulfil the requirements given for 
reproductive toxicity testing of pesticides in the European Commission directive 91/414/EEC and in the 
amendment 94/79/EEC and, therefore, are not conclusive.
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The aims were to study occupational exposure and exposure routes to coal tar creosote, and to evaluate 
the methods that are most suitable  in monitoring of occupational exposure to PAHs in creosote.   
 
The aims were: 
 
1. To characterise the composition of creosotes used in Finland and to test the genotoxicity of different 
creosotes in relation to their PAH content (II) 
 
2. To carry out a pilot study on the kinetics of naphthalene metabolism in humans (unpublished data) 
 
3. To identify the composition of airborne impurities, and to monitor the level of workers' exposure 
during creosote impregnation process and during the use of impregnated wood (I, III-V)  
 
4. To estimate the dermal exposure of workers exposed to creosote (III-V) 
 
5. To evaluate the suitability of the biological monitoring of two urinary metabolites for exposure 
assessment (III-V)
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6. Materials and Methods 
6.1. Creosotes 
The chemical composition of four creosotes used for the impregnation of wood in Finland at the end of 
the 1980s was analysed (II). The Polish and German creosotes were supplied by Vierumäen Teollisuus 
Ltd, the Danish creosote by Metsä-Serla Ltd, and the creosote originating from the Soviet Union was 
supplied by the Finnish Wood Preserving Association. The products fulfilled the requirements of British 
Standard 144:1973 type 1 creosote oil. The analysed creosotes originated from the same suppliers as the 
creosotes used in impregnation during the exposure measurements.  
 
6.2. Subjects, workplaces and the collection of air and urine samples 
6.2.1. Field studies 
Surveys were conducted in two impregnation plants as well as in the handling of impregnated timber 
during the summer of 1985 and of 1987 (I, III-IV). One plant impregnated railway ties, and the other 
one electrical poles. The handling of impregnated timber included the assembling of railway switches 
indoors, the repairing of railway switches and rails outdoors, including the welding of rails, and the 
loading of impregnated poles onboard a ship. Airborne impurities were monitored during one to two 
shifts in 1985, and urinary concentrations of 1-OHN and 1-OHP were measured concurrently with the 
airborne concentrations in the railway tie plant, and in the switch assembly shop during one work week 
in 1987. The summary of the air and urine measurements is presented in Table 10. 
 
Railway ties were impregnated with a mixture of Polish and Soviet creosotes (2:1) in 1985, and with 
Polish creosote in 1987. The creosote used for poles was imported from the Federal Republic of 
Germany. The number of workers in the impregnation plants ranged from 8 to 15/plant. In addition to 
the impregnation workers, four men at the tie plant fixed metal plates onto the impregnated railway ties. 
The number of persons monitored in the present study is given in Table 10. The impregnation cylinders 
were opened 1-3 times a day. During the opening (5-15 min), workers near the cylinder can be exposed 
to high peak concentrations. The cylinder was opened manually in the tie plant, and mechanically in the 
pole plant. All workers wore leather gloves and cotton overalls, but no one used a respiratory protector. 
 
Four assemblers fitted together railway switch components in a shop where mechanical ventilation was 
functioning during the  summer. The railway ties had been treated with Polish creosote, and they had 
been stored for a year after impregnation to reduce staining. All assemblers wore leather gloves and 
cotton overalls, the shanks of which were coated with plastic fabric. 
 
Rails and switches were repaired and renewed in a railway yard and along the railways by installing new 
switch components, and replacing old rotten ties with new ones, and by welding. Ten workers were 
employed in setting new switch components in the railway yard, where also 8 000 freshly impregnated 
ties were piled. The rails of the switch components were joined by thermite welding (1000 °C). A group 
of six men replaced moulded ties with new ones, which were transported on a wagon and dropped 
beside the rails; the old ties were removed and the new ones assembled mechanically. Two men repaired 
the old rails by manual metal arch welding (MMA). Before welding, the rail was preheated to 420-600 
°C, and also the ties were heated. All workers wore leather gloves and cotton overalls (I). Welding 
fumes were normally diluted by injecting air with a fan, but during the sampling no fan was used. 
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The exposure of stevedores was monitored at two ports. From one to three men loaded poles on a dock, 
a crane lifted the  piles of poles, and 1-2 men piled them onboard a ship (I). 
 
Table 10. The sampling sites, the number of samples, the prevalence of exposure and the measured 
exposure indicators. 
 
Work site/plant/year/  Sampling 
 time 
Exposure/ 
day and year
Measured exposure indicators, 
n=number of persons monitored 
N=number of samples collected 
Dermal 
exposure 
Ref. 
Wood impregnation 
  Plant 1, 1985 
 
  Plant 1, 1987 
 
 2 shifts 
 
 5 shifts 
 
8 h/11 mo 
 
8 h/11 mo 
 
Vapours and particulate PAHs in air 
n=9, N=26 
Vapours and particulate PAHs in air 
n=6 , N=60 
Urinary 1-OHN and 1-OHP 
n=6,  N=125 
 
High 
 
I 
 
 
III, 
V 
  Plant 2, 1985  1 shift 
 
6-8 h/varies Vapours and particulate PAHs in air 
n=4,  N=8 
High I 
Handling of treated 
wood 
  Assembly shop, 1985 
 
  Assembly shop, 1987 
 
 1 shift 
 
 5 shifts 
 
 
8 h/11 mo 
 
8 h/11 mo 
 
Vapours and particulate PAHs in air 
n= 2, N=8 
Naphthalene in air 
n= 3, N=14 
Urinary 1-OHN and 1-OHP 
n= 3, N=47 
 
High 
 
I 
 
 
IV 
  Rail welding, 1985  3 h 
 
2-4 h/4-11 mo Vapours and particulate PAHs in air 
n= 2, N=4 
No/Low I 
  Construction of 
   switches, 1985 
 1 shift 
 
5-8 h/4-6 mo Vapours and particulate PAHs in air 
n=3 , N=4 
Medium I 
  Repairing of old rails, 
  1985 
 2 h 
 
2-8 h/4-6 mo Vapours and particulate PAHs in air 
n=3 , N=3 
Low I 
  Loading on ship, 1985  2 h 
 
≤5 h/0.5-2 mo Vapours and particulate PAHs in air 
n= 2, N=9 
High I 
 
 
The sampling time of airborne impurities covered one to two full shifts or the active working hours in 
1985, and five consecutive shifts in 1987. Concurrently with the monitoring of the air impurities in 
1987, all the urine voided during 24 h was collected from the workers during three work days (Monday, 
Wednesday and Friday) in five composite samples. The workers were also asked to provide urine 
samples over the following weekend. The five-day sampling period was preceded and followed by a 
work-free period of 64 h. Smoking status was inquired by personal interviews. Three out of six 
impregnation plant workers, and all the switch assemblers were smokers. The concentrations of 
particulate PAHs in the assembly shop in 1987 were estimated from the results of the measurements 
carried out in 1985 in the assembly shop. The ratio between the concentrations of naphthalene and 
pyrene in 1985 was used to calculate the concentration of pyrene in air in 1987. 
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6.2.2. Kinetic pilot  studies with naphthalene 
The excretion of naphthalene in human volunteers was investigated in a pilot study (unpublished data). 
The kinetics of naphthalene metabolism was examined following oral, dermal and respiratory exposure. 
The volunteers were two healthy, non-smoking, adult research workers: a woman (age 43 years, weight 
59 kg) and a man (age 46 years, weight 73 kg). The volunteers were informed about the purpose of the 
study, the methods, potential risks of naphthalene, and their right to decline from the study. The pilot 
study followed the recommendations in the Declaration of Helsinki 170. The risks caused by a single oral 
dose (29.5-36 mg), inhalation or dermal absorption of naphthalene were considered to be low. There is 
no information on the effects of naphthalene following acute inhalation or dermal exposure in humans. 
Acute haemolytic anaemia due to naphthalene has been described in several children and adults who 
have accidentally eaten mothballs144. 1- OHN has been proposed to be a causative factor 144, 147, 148. The 
amount of naphthalene ingested has not been reported in the studies, but mothballs usually weigh 500 -
3600 mg. The published studies suggest that naphthalene is not genotoxic 3. No data are available on the 
carcinogenicity of naphthalene in humans. In a two-year inhalation study with mice, naphthalene has 
had no carcinogenic activity in male mice exposed to 10-30 ppm. Increased incidences of 
alveolar/bronchiolar adenomas were found in female mice at a site where inflammatory changes also 
occurred 150.  
 
The subjects ingested in a single dose, 0.5 mg/kg of naphthalene dissolved and mixed in 2 ml of ethanol 
and mixed with 0.2 l of a cola drink. The excretion of 1-OHN was followed by collecting all the voided 
urine in separate samples every 2nd hour for the first 8 h and spontaneous voids thereafter for 24 h. 
Control urine specimens were collected before the experiment. 
 
The same two volunteers applied 0.5 mg/kg naphthalene dissolved in 2 ml diethylether on an area of 
about 23-25 cm2 on their ventral forearm skin. The compound was kept under occlusion for 4 h and then 
washed away with soap and water. The excretion of naphthalene was followed by collecting all the urine 
voided every 4th hour for the first 8 h and then spontaneously for 24 h. Control samples were obtained 
before the experiment. 
 
The experimental inhalation exposure was conducted in a dynamic exposure chamber. Naphthalene-
containing air was generated by mixing saturated naphthalene vapour with laboratory room air drawn 
into the chamber. The stability of the naphthalene concentration was controlled by an infrared 
spectrophotometer (Miran 1A) automatically with the aid of a processor by varying the feed rate of 
saturated naphthalene vapour. The airborne concentration was confirmed by collecting samples onto 
three XAD-2 resin tubes. The samples were analysed by HRGC equipped with a FID detector. The 
concentration of naphthalene was 0.8 mg/m3 by HRGC and 0.8-1.0 mg/m3 by Miran 1A. The exposure 
time was 3 h 56 minutes. All the voided urine was collected in separate samples, first every 4th hour and 
then spontaneously. Control samples were obtained before the experiment. 
 
For the estimation of uptakes via different routes, the following assumptions were made: 
 
- Naphthalene was completely absorbed after oral ingestion 111. 
- Inhalation uptakes were derived by assuming that lung ventilation of the volunteers was 15 l/min 
(non-intensive work) 171, and that 50% of naphthalene was retained in the lungs.  
 
No data were available on the retention of naphthalene following inhalation. The assumption of 50% 
was based on the knowledge that only a part (70 %) of inhaled air reaches the alveoles where gaseous 
6. Materials and Methods 
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 120  45   
exchange can take place 171, and that the pulmonary retention or uptake of vaporous aromatic 
compounds such as xylenes, toluene and benzene has been 56-59% 172, 53% and 50% 173, respectively, 
in humans. These compounds contain one aromatic ring, whereas naphthalene is formed of two aromatic 
rings, and they all are lipophilic. Over 99% of airborne naphthalene is in the vapour phase.  
 
These default values give the inhalatory dose: 0.5*15 l/min*236 min*0.8 mg/m3 =  1.4 mg 
 
The fraction of 14C-naphthalene absorbed through the skin after dermal application in rats has been 50% 
112, but no quantitative data on the absorption of naphthalene in humans are available. Neither are data  
available on the percentage of naphthalene excreted as 1-OHN in urine in humans after dermal 
exposure. The pattern of the metabolites of naphthalene differs in animals and humans 111, 112, and 
therefore animal studies cannot be used for extrapolation to human. In this study, the ratio (7%) of 
excreted urinary 1-OHN to estimated uptake via lungs (Table 13) was used in extrapolating  the 
percentage of naphthalene absorbed after dermal application. 
 
6.3. Sampling and analytical methods 
6.3.1. Creosotes 
The samples of four creosotes were fractionated into four chemical classes on a neutral aluminium oxide 
column: aliphatic hydrocarbons, neutral aromatic hydrocarbons, sulphur- and oxygen-containing 
aromatic compounds, and nitrogen-and hydroxyl-group-containing aromatic compounds 174. The 
creosotes and chemical fractions were analysed and their components identified semiquantitatively 
using a HRGC equipped with FID, with MS or an alkali thermoionisation detector. The identification 
was based on a mass spectral database (Finnigan MAT, NBS Library Compilation), retention times and 
reference substances 140, 175. Deuterated phenanthrene (C
14
D
10
) was used as an internal standard. The 
percentage of each component was calculated from the sums of the heights of the single peaks in the 
total ion chromatograms. In addition to the HRGC analysis, the content of 13 PAH was quantified by 
HPLC in the creosotes and in the distilled fractions of the creosotes (II). The creosote samples that were 
analysed originated from the same batches that were used in the impregnation plants. 
 
6.3.2. Genotoxicity tests 
The four creosotes were tested in two bacterial genotoxicity tests: the Ames Salmonella test and a semi-
automated version of the SOS chromotest (II). The Ames Salmonella tests were performed according to 
the standard plate incorporation protocol with Salmonella typhimurium strains TA98, TA100, the 
nitroreductase overproducing strain YG1021, and the O-acetyltransferase overproducing YG1024. The 
strains YG 1021 and 1024 have increased sensitivity to detect mutagenicity of aromatic nitro- and 
amino-compounds 176.  
 
In addition, the mutagenicity of urine samples (at the end of shift samples) from six workers in the tie 
impregnation plant was tested by using the Salmonella typhimurium strains TA 100 metabolically 
activated with S9 mix 177. Three out of six workers were smokers. 
 
Tests were performed with and without metabolic activation with S9 mix. Mutagenic activities were 
calculated for the test samples in which a doubling was observed in the colony counts. The creosote 
samples were distilled according to their natural boiling ranges into 4-6 fractions under normal pressure. 
The mutagenic activities of the fractions were studied with Salmonella typhimurium strains TA98 and 
Pirjo Heikkilä: Respiratory and Dermal Exposure to Creosote 
 
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 120 46
TA100 in the presence of S9 mix. The taped plate assay was performed by adding creosotes and 
fluoranthene onto the bottom plates, and the tester strains were added onto the top plates together with 
the S9 mix. In addition, the sister-chromatid exchange (SCE) test with Chinese hamster ovary (CHO) 
cells was performed (II). 
 
6.3.3. Air samples 
Four sampling methods to collect vaporous emissions from creosote were compared in the laboratory 
experiments; a sample of the Polish creosote was heated to 60°C in a chamber, and evaporated 
contaminants were collected simultaneously into an absorption solution (toluene), on activated charcoal, 
on silica, and on XAD-2 resin. The samples were analysed by HRGC/MS, and 28 compounds were 
identified. In a qualitative comparison, the same peaks could be identified in the samples collected with 
absorption solution, silica and XAD-2 resin, but many components were lacking in the sample collected 
on activated charcoal. On the basis of these qualitative results, XAD-2 was selected for further testing. 
The recovery of the main components was studied at one concentration from five parallel samples. The 
concentrations were analysed by HRGC with a FID detector. The recovery of the tested main 
components ranged from 82-102%. The detection limit for the identified compounds was 1-5 µg/sample 
corresponding to airborne concentration of 0.01-0.05 mg/m3 for an air volume of 100 litres. The samples 
were collected on XAD-2 resin at a flow rate of 0.2 l/min at the workplaces. The calculated total 
concentration of vapours is the sum of the concentrations of the compounds identified in the vapour 
samples from the work sites (I). 
 
The concentration of particulate PAHs was measured by collecting samples onto the prewashed glass 
fibre filters at a flow rate of 2 l/min. The samples were extracted with cyclohexane, and the solution was 
then evaporated to dryness and dissolved ultrasonically in acetonitrile. The analysis was completed with 
reversed phase HPLC and fluorescence detection. A detection limit of 5 pg of BaP was achieved. This 
corresponds to an air concentration of about 8 ng/m3 for a 100 l air sample. The presented total 
concentration of PAHs is the sum concentration of 11 particulate PAHs (I). 
 
6.3.4. Urine samples 
The urinary concentration of 1-OHN was analysed by HRGC with an EC detector as a 
pentafluorobenzylbromide derivative 63, 64. Urinary 1-OHN was hydrolysed with concentrated 
hydrochloric acid and extracted with dichloromethane. The recovery of the added standards from the 
urine was 66.2±3.3%. The concentrations of 1-OHN in all urine samples were normalised either to urine 
density of 1.024, or corrected for creatinine content (IV, V). 
 
The urinary concentration of 1-OHP was analysed by a HPLC method with fluorescence detection 66. 
The urine samples were enzymatically hydrolysed with ß-glucuronidase and arylsulphatase, then 
purified and enriched using solid phase extraction cartridges C18 with methanol as an eluent. The 
recoveries of the added standards were 65-80%. The concentrations of 1-OHP in the individual urine 
samples were corrected for creatinine content  (III, IV). 
 
Elimination half times were estimated among workers engaged in the railway switch assembly; the 
elimination rates of 1-OHN and 1-OHP in urine seemed to follow a two-compartment model. The slow 
elimination phase for 1-OHP was resolved from the linear regression line drawn through the last two 
points and, for 1-OHN, through the last four points of the weekend measurements. The slope of the first 
phase was resolved by the method of residuals 178 (IV). 
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6.4. Estimation of uptake of naphthalene and pyrene among the workers 
To gain further insight into the likely routes of exposure at work, the inhaled and absorbed naphthalene 
and pyrene doses were estimated and compared to the excreted amounts of their 1-hydroxy metabolites 
over 24 h.  
 
Inhalation uptakes were derived by assuming that the lung ventilation of workers was 25 l/min (medium 
intensive work) 171, and that uptake of naphthalene (see section 6.2.2.) and pyrene in the lungs was 50%.  
 
The pulmonary retention of pyrene has been measured to be 61% among volunteers in an aluminium 
plant 113. But pulmonary retention (ratio of the difference between inhaled and expired air concentrations 
to that of inhaled concentration) is a valid method only for compounds that are in vapour or gaseous 
phase, but not for particles that are deposited on airways. Pyrene appears in the air in impregnation 
plants as vapour (50%) and bound on particles (50%) 43.  
 
Van Rooij 6 and Quinlan 37 have used the following assumptions in converting pyrene air concentrations 
to intaken pyrene doses: 
 
- The pulmonary retention of vaporous pyrene is 70% 
- The resorption factor for particulate pyrene is 12.5%  
- 62.5% of the inhaled particles are swallowed, and 40% are absorbed from the gastrointestinal track.  
 
Man is exposed to particulate PAHs via two routes, inhalation and intestinal route, because particles 
deposited on the respiratory tract are partly removed by mucociliary transport to the glottis 114. Van 
Rooij's calculations for particle-bound pyrene were based on the assumptions presented by the 
Environmental Protection Agency in USA 179 and on an animal study on the pharmacokinetics of 
BaP 180. These assumptions yield 50% uptake for airborne pyrene. This value was adopted for the 
calculations of the inhaled pyrene doses in this study. The deposition and clearance of particles depend, 
however, on many factors, e.g. on the particle size, breathing rate and route of breathing, and thus the 
doses calculated in this study are not exact figures but rather describe the magnitude of the absorbed 
doses.  
 
Inhalation uptakes were derived as follows: 
 
Dose = Ctotal * V * T * R 
 
Where 
Ctotal is the concentration of naphthalene or that of vaporous and particulate pyrene in air  
V = ventilation rate for a worker (25 l/min during medium intensive work)  
T = exposure time  
R = 50 % retention or uptake.   
 
The excretion of the substance over 24 h can be thought to represent uptake over the workday, even 
though a true steady-state did not exist, as the exposures varied from day to day. The calculation of the 
absorbed pyrene doses via inhalation is based on the sum concentration of vaporous and particulate 
pyrene. 
 
To further determine the impacts of respiratory and dermal exposure for the total body burden of 
workers in the tie plant and for workers handling treated wood, the following assumptions were made: 
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-7% of the naphthalene taken up via the lungs and the skin was excreted in urine as 1-OHN (the 
arithmetic mean value of the kinetic study results) 
-4% of the pyrene taken up via the lungs and the skin was excreted in urine as 1-OHP 131. 
 
Because no quantitative human data on the percutaneous absorption of naphthalene or pyrene were 
available, the results calculated for naphthalene in the kinetic study were also adopted for pyrene (18% 
of the naphthalene applied on the skin was absorbed). 
 
6.5. Statistical methods 
The normality of the data on the distributions of the air and urinary analyses of the original and the log 
transformed data variables were checked. The distributions of the airborne and urinary concentrations 
were closer to lognormal than normal. Pearson’s correlation (linear regression) was used for the 
correlation between the concentrations of the analysed compounds in creosotes and their mutagenic 
potency. Spearman's correlation coefficient was used to test the correlation between the concentrations 
of naphthalene, pyrene and their urinary metabolites. With concentrations below the detection limits, 
values equivalent to half of the detection limits were used in calculating the airborne concentrations 181. 
7. Results 
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7. Results 
7.1. Composition of creosotes and genotoxicity 
About 85 components were identified in four creosote products (96-98% of the total composition). The 
main components were alkylphenols, biphenyls, naphthalene and its alkyl derivatives, phenanthrene, 
fluorene, acenaphthene, and dibenzofurane in all the samples (II). The sum concentration of PAH with 
2-3 aromatic rings was about the same (60-62%) in all analysed creosotes, but there were considerable 
differences (1.3-8.6%) in the content of PAHs with ≥ 4 aromatic rings. The weight percentages of these 
PAHs and BaP were highest in the Danish creosotes (Table 11).  
 
The concentrations of pyrene and BaP correlated with the concentration of ≥ 4 aromatic ring PAHs (the 
correlation coefficients 0.90 and 0.98). The lower pyrene and BaP content in creosote oils thus indicated 
the lower ≥ 4 aromatic ring PAH content. Also the naphthalene content had a linear relationship with the 
concentration of  ≥ 4 aromatic ring PAHs (correlation coefficient 0.98). 
 
The identified nitrogen compounds were almost exclusively heterocyclic, aromatic compounds such as 
pyridine, quinolines, acridine and carbazole. In addition, nitrogen compounds included aminofluorenes 
and cyano-PAH, such as cyanonaphthalene, cyanoanthracenes and cyanofluorene. The content of 
nitrogen compounds was in the range of 4.4-8.2 weight-%. All identified sulphur compounds were 
heterocyclic thiophenes and their derivatives. Inaddition to phenolic substances, the oxygen-containing 
compounds consisted also mainly of heterocyclic aromatic compounds such as benzofuranes (Table 3 in 
II). 
 
Table 11. Chemical composition (weight-%) of four creosotes (II). 
 
Chemical class German Danish Polish Soviet 
Naphthalene 9 17 10 11 
BaP 0.07 0.34 0.005 0.048 
Pyrene 1.8 1.9 0.2 0.8 
PAHs (≥ 4 aromatic rings) 4.8 8.6 1.3 2.4 
N compounds 4.4 2.7 8.2 4.4 
S compounds 1.8 2.9 2.1 2.2 
O compounds 13.6 9.6 10.1 14.5 
 
All creosotes gave positive results in mutagenicity tests with Salmonella typhimurium strains TA98, 
YG1021 and YG1024 in the presence of mutagenic activator S9 mix. The rank order of the mutagenic 
potency, in decreasing order, was Danish, Soviet, German and Polish creosotes, and the content of six 
mutagenic PAHs and BaP correlated with the mutagenic potency of the creosotes (correlation 
coefficients 0.94 and 0.98) (Table 5 in II). The results showed that the mutagenicity resides in fractions 
having the high boiling ranges and a high content of mutagenic PAHs (Table 2 in II). Only the German 
and Danish creosotes were positive when tested with strain TA100+S9 mix. The mutagenic activities of 
the distillation fractions, containing higher concentrations of PAHs than the creosotes, generally 
displayed lower activities than the original creosotes (Table 5 in II). Only one fraction of the Polish 
creosote had a slightly higher mutagenic activity than the whole creosote. The results indicate that the 
content of PAH or BaP alone does not fully explain the genotoxic potency of the creosotes.  
 
No increase in the mutagenicity of the urine of the impregnation plant workers was detected that could 
be related to their work 177. The results from the taped plate assay were negative for all creosotes, 
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obviously because of the low concentration of mutagenic compounds in the vapours emitted in the test 
conditions at 37 °C (II). 
 
7.2. Air and urine monitoring 
Naphthalene, methylnaphthalenes, indene, phenol and its methyl homologues, methyl styrene, 
benzothiophene, diphenyl, acenaphthene and fluorene were the main components in the vapour phase. 
The percentage of naphthalene in the total concentration of vapours was on average 52% in 
impregnation plants, and 32% in the handling of treated wood. Naphthalene and the total concentration 
of vapour had a good linear correlation both in the impregnation plants and in the handling of treated 
wood (correlation coefficients 0.99 and 0.97). The main components of particle bound PAHs were 
fluorene, phenanthrene, anthracene and pyrene (I). 
 
The total TWA concentrations of vapours varied within the range of 0.5-9.1 mg/m3 in the impregnation 
plants, and 0.1-11 mg/m3 in the handling of the treated wood (I). During cleaning of the creosote 
warming chamber, the workers were exposed to high peak vapour concentrations (35-71 mg/m3). The 
TWA concentration of the main component, naphthalene, was 0.2-5.7 mg/m3 in the impregnation plants, 
and 0.06 - 4.3 mg/m3 during the handling of impregnated wood (I, III, V). The mean concentrations of 
vapours were highest in the breathing zone of those wood preserving workers who stayed in the vicinity 
the cylinder during its opening (assistant operators 9.1 mg/m3), and of the assemblers fitting together 
impregnated sleepers during winter conditions (11 mg/m3) in a hall. The vapour concentrations also 
were above the arithmetic mean near a tie stock (7.0 mg/m3) outdoors on a sunny day (I). 
 
The air concentrations of particulate PAHs ranged from 0.2 to 46 µg/m3. The arithmetic mean 
concentration of BaP in the impregnation plants was 0.01 µg/m3 except during opening of the cylinder 
(0.06 µg/m3).  In the switch assembling  hall, the BaP concentration was 0.02 - 0.24 ug/m3. The highest 
level was measured in the breathing zone of a worker boring holes in sleepers. The profiles of 
particulate PAHs were different in the impregnation and in the handling of treated wood, compared to 
the welding of rails (Fig. 3 in I). In the former case, over 90% of particulate PAHs consisted of 3-ring 
PAH compounds (fluorene, phenanthrene and anthracene), whereas in the latter, 50% of the measured 
PAHs were 4-6 ring PAH compounds. The exposure via lungs to particulate PAHs (44 µg/m3) and to 
BaP (0.39-0.89 µg/m3) was highest among the rail welders (I). In wood impregnation and in the 
handling of treated wood over 99% of the airborne impurities consisted of vaporous compounds, except 
during the welding of rails when the percentage of particulate PAHs was 4%. 
 
The TWA concentrations of naphthalene, pyrene and BaP in air, and the urinary concentrations of 1-
OHN and 1-OHP in the end-of-shift samples are summarised in Table 12. 
 
At the impregnation plants, the urinary 1-OHN and 1-OHP concentrations in the end-of-shift samples of 
the non-smoking (1460 and 68 µmol/mol creatinine, the number of samples was 9) and smoking (1240 
and 55 µmol/mol creatinine, the number of samples was 9) workers were not significantly different 
(P=0.22). Three out of six impregnation plant workers were smokers. 
 
After the weekend, on Monday morning, the levels of urinary 1-OHN and 1-OHP were clearly higher 
than among non-occupationally exposed persons: for the impregnation plant workers, 49 µmol/mol 
creatinine and 13 µmol/mol creatinine, and for the assemblers 18 µmol/mol creatinine and 0.6 µmol/mol 
creatinine, respectively (III, V). The Monday morning urinary 1-OHP concentration (13 µmol/mol 
creatinine) of the impregnation plant workers was about two times the mean of 1-OHP in the end-of-
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shift urine of the assemblers (6.8 µmol/mol creatinine). The maximum concentration of 1-OHN was 
measured at the end of the shift, and that of 1-OHP in the evening or of next morning (III, IV, V). 
 
The correlation between the TWA concentration of naphthalene and the end-of-shift urinary 1-OHN 
concentration was good (0.75) for the impregnation plant workers (V) but poor (< 0.5) for the 
assemblers (IV). Similarly, the correlation between pyrene in air and urinary 1-OHP were low (< 0.5) 
for the these two groups (III, IV). 
 
The study findings suggest a two-phase excretion of 1-naphthol and 1-pyrenol in urine. There seems to 
be a more readily excreted part of 1-OHN and 1-OHP (rapid compartment) exhibiting half-lifes of 1.2-
1.9 h for 1-OHN and 5-6 h for 1-OHP. The apparent biological half-life of the second phase was 14-46 h 
for 1-naphthol and 22-24 h for 1-pyrenol (IV) 
 
7.3. Pilot studies on the kinetics of naphthalene 
Figure 2 shows the excretion curves and Table 13 shows the excreted amounts of the 1-hydroxy 
metabolite/ 24 h obtained in the two volunteers following oral, dermal and respiratory exposure to 
naphthalene. The urine voids collected by the male volunteer were incomplete after the ingestion of 
naphthalene.  
 
The timing of peak urinary excretion of 1-OHN after dermal and respiratory exposures was different for 
the study persons (Fig. 2B). Detectable amounts of 1-OHN appeared in the urine at 4 h after starting the 
skin absorption experiment (284-540 µmol/mol creatinine), and detectable concentrations were 
measured over 13-17 h post-exposure.  
 
When the previously given assumptions (section 6.2.2.) were used for the calculation of respiratory 
uptake, in average 7% of the naphthalene taken via lungs was excreted in urine as 1-OHN. After dermal 
application, 1-2% of naphthalene applied on the skin was found in urine as 1-OHN (Table 13). In order 
to estimate the amount of naphthalene that was absorbed through the skin, further assumptions were 
made on the metabolism of dermally taken naphthalene. Adopting the result from the inhalation study, 
i.e. that about 7% of naphthalene taken up was excreted as 1-OHN, shows that 11-26% (mean 18%) of 
the naphthalene applied on the skin was absorbed. The reason for assuming that the metabolic fate of 
naphthalene is rather similar following absorption via the lungs and the skin, whilst it may be different 
after ingestion, is the likely firstpass metabolism in the liver after oral absorption. 
 
There may be striking individual differences between individuals. Many factors such as genetic factors 
(e.g. sex, interindividual polymorphism), exogenous chemicals (e.g. induction) and nutrition can affect 
PAH metabolism 182. Because only two subjects were tested, the results of the kinetic study are only 
indicative. As has been demonstrated with phenanthrene, the metabolism of PAHs can vary significantly 
interindividually 128. The calculated uptakes by different routes include several assumptions, but no 
other quantitative data are available on the absorption of naphthalene via different routes  in humans. 
 
The calculated half-lifes of naphthalene  fit best into one compartment model in inhalation (3-13 h) and 
dermal (3-7 h) exposure. Two consecutive half-lifes were observed in the ingestion experiment (1st 
phase 1h and 2nd phase 4-6 h)  . It is apparent that excretion also follows the two-compartment model in 
inhalation and dermal exposures, but the absorbed amounts were too small to be quantified during the 
2nd phase. 
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   Table 12. The concentrations of some PAHs (µg/m3) in air and of two metabolites in urine (µmol/mol creatinine) at the end of the shift. 
 
Work site/plant Naphthalene Pyrenea BaP 1-OHP 1-OHN Ref.
Wood impregnation  
Plant 1 (railway ties), 1985
Plant 1, end of shift, 1987 
  Mon morning 
  Fri morning 
 
Plant 2 (poles) 
 
2200 (440-5700) 
1540 (370-4200) 
 
 
 
650 (500-800) 
 
1.1(0.9-1.9) 
0.97(0.23-2.10) 
 
 
 
0.11(0.01-0.2) 
 
0.01(0.01-0.03) 
0.01(<0.01-0.05) 
 
 
 
<0.01 
 
 
64 (14-167) 
13 (4-16) 
68 (22-106) 
 
 
1350 (220-2950) 
49 (30-70) 
249 (38-419) 
 
I 
III, V 
 
 
 
I 
Handling of treated wood 
Assembly shop, in 1985 
Assembly shop, in 1987 
  end of shift 
  Mon morning 
  Fri morning 
 
Rail welding 
Construction and repairing 
of rails 
Loading on ship 
 
2600 (870-4320) 
1000 (200-2000) 
 
 
 
 
200 (50-320) 
1100 (80-2230) 
 
400 (60-1100) 
 
0.6 (0.1-0.80) 
0.4 (0.06-0.70) 
 
 
 
 
13 (2.5-24.8) 
0.6 (0.03-2.1) 
 
0.07(0.01-0.12) 
 
0.02(<0.01-0.26) 
 
 
 
 
 
0.64 (0.39-0.89) 
<0.01-0.01 
 
<0.01 
 
 
 
6.8 (3.8-12.8) 
0.6(0.4-0.9) 
6.8(3.9-12.2) 
 
 
 
 
1330 (254-2330) 
18 (<5-35) 
187 (79-511) 
 
 
I 
IV 
 
 
 
 
I 
I 
I 
Referents 
smokers + non-smokers 
smokers 
    
0.23b
 
 
<7c
 
 
V 
a particulate pyrene 
b the reference value for those non-occupationally exposed in Finland 33  
c the number of referents was 5  
For the number of samples collected and persons monitored see Table 10. 
.
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Table 13. The naphthalene doses and the measured excretion of 1-OHN in the experimental study. 
 
Route of 
exposure 
Sex Dose Administered or 
estimated taken dosea
Voided 
urine/24 h 
Excreted 
1-OHN 
Ratio, excreted/taken 
or administered 
  mg/kg mg µmol L (µmol)  
ingestion male 0.5 36b 281b 0.6c  c
 female 0.5 29.5b 230b 1.4 112 0.49 
dermal male 0.5 36d 281d 1.3 4.4 0.02 
 female 0.5 30d 234d 1.5 2.26 0.01 
  mg/m3      
inhalation male 0.8  1.4b 11b 1.6 0.7 0.06 
 female 0.8  1.4b 11b 1.9 0.94 0.09 
a  The assumptions used in the estimation are presented in section 6.2.2. 
b  Estimated absorbed dose 
c  All urine voided in 24 h was not collected 
d  Administered dose 
 
7.4. Estimation of absorbed doses and dermal exposure 
The mean 24-h excretion of 1-OHN was 8.8 µmol among the impregnation plant workers and, when 
adopting the results of the experimental kinetic study, the expected excretion derived from the inhaled 
naphthalene was 3.9 µmol. This suggests that 56% of the absorbed naphthalene entered the body by 
other routes than the lungs, notably via the skin, and that the daily absorbed naphthalene dose was on 
average 125 µmol (Table 14). The corresponding estimated ratio for the assemblers was 70%, and the 
absorbed average dose was 117 µmol. The predicted excretion of 1-OHP derived from inhaled pyrene, 
when both vaporous and particulate pyrene were included in the inhaled dose, was less than 1% of the 
measured 24-h excretion of 1-OHP, suggesting that essentially all pyrene was taken percutaneously. The 
estimated, daily absorption of pyrene for the impregnators and the assemblers was 22 µmol and 3 µmol, 
respectively. 
 
The ratio of excreted 1-OHN/inhaled naphthalene uptake and that of excreted 1-OHP/inhaled pyrene 
uptake varied widely from day to day and from worker to worker. The highest ratios of excreted 1-
OHN/inhaled naphthalene were calculated for two switch assemblers in one day (1.5-2.6) being 10 times 
higher than during other work days (0.09-0.15) or than for the third assembler (0.01-0.3) (Table 3 in 
IV). The ratios of excreted 1-OHP/ inhaled pyrene uptake displayed 6-7-fold differences between 
workers in both work places (Table 4 in III, Table 3 in IV). 
 
Adopting the results of the kinetic study (18% of naphthalene applied on the skin is absorbed) gives the 
following daily skin contamination (dermal exposure) estimations: 
 
  Naphthalene on skin Pyrene on skin 
Impregnation plant workers 50 mg /worker/day 27 mg/worker/day 
Assemblers                                     60 mg /worker/day  3.3 mg/worker/day 
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Figure 2. The excretion of 1-hydroxynaphthalene after oral (A), respiratory and dermal administration (B) in 
the experimental kinetic study in two volunteers. 
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Table 14. Estimated uptakes of naphthalene and pyrene via lungs and skin among creosote workers. 
 
 Work site Absorbed 
substance via 
inhalation 
 
Excreted 
metabolite 
Calculated 
excretion 
derived from 
inhalationb
Absorbed 
substance  
via skinb
Total daily 
uptakeb
 
Ratio of 
dermal to  
total 
uptake 
 Naphthalene 
(µmol/day) 
1-OHN 
(µmol/day) 
1-OHN 
(µmol/day) 
Naphthalene 
(µmol/day) 
Naphthalene 
(µmol) 
 
 Impregnation  
 plant,  
 N=6 
55  
(7 mg) 
8.8  
(1.1 mg) 
3.9  
(0.5 mg) 
70 
 (9 mg) 
125 
 (16 mg) 
56 % 
 Assembly  
 shop,   
 N=3 
35  
(4.5 mg) 
8.2  
(1.0 mg) 
2.8  
(0.36 mg) 
82  
(10.5 mg) 
117  
(15 mg) 
70 % 
 Pyrene a)
(µmol/day) 
1-OHP 
(µmol/day) 
1-OHP 
(µmol/day) 
Pyrene 
(µmol/day) 
Pyrene 
(µmol) 
 
 Impregnation  
 plant,   
 N=6 
0.06  
(0.013 mg) 
0.89 
(0.16 mg) 
0.002 22 
 (4.9 mg) 
22 
 (5 mg) 
>99 % 
 Assembly 
 shop,   
 N=3 
0.03 
 (0.006 mg) 
0.12 
(0.022 mg) 
0.001 3  
(0.6 mg) 
3  
(0.6 mg) 
>99 % 
a) Estimated inhaled pyrene dose includes vaporous and particulate pyrene 
b) Assuming that 7% of naphthalene taken up by inhalation is excreted as 1-OHN, and correspondingly 
4% of pyrene is excreted as 1-OHP 
N = Number of persons 
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8. Discussion 
8.1. Composition of creosotes and genotoxicity 
In agreement with the literature 21, 23, 24, 26-29, the composition of the creosotes used in Finland varied 
greatly. The percentage of PAHs with 2-3 rings was about the same in all the creosotes, but the contents 
of other compounds differed widely; the difference in the BaP content was 60-fold between the lowest 
and highest values (50-3400 ppm). This is consistent with the concentration range of BaP reported in the 
literature (200-4300 ppm) (Table 4). The ranges of naphthalene and pyrene concentrations reported in 
the literature 21, 23-26, 28, 29 have been greater (1.3-18% for naphthalene, 0.1-8.5% for pyrene) than those 
analysed in this study (9-17% and 0.2-1.9%). Since 1995, when Finland implemented the EU directive 
94/60/European Commission, which regulates the use and content of BaP and phenols, the creosote 
products used in Finland have fulfilled the BaP limit value of 50 ppm (the Finnish Wood Preserving 
Association). The level of BaP correlated with the concentration of ≥ 4 aromatic ring PAHs. The lower 
BaP content also resulted in a lower ≥ 4 aromatic ring PAH content of the analysed creosotes; this is  
probably true also in the case of other creosotes.  
 
All the creosotes were mutagenic in the presence of metabolic activation, as could be expected from the 
literature 151, 152. The genotoxicity of creosotes correlated with the content of BaP and mutagenic PAHs. 
The creosote with 50 ppm BaP was already mutagenic in the Ames tests, although its activity was lower 
than that of the creosotes with a higher BaP content. It has been estimated that the genotoxicity of a 
chemical compound predicts carcinogenicity for about 60% of chemicals 183. Thus the lowering of the 
BaP content of creosotes possibly decreases their carcinogenic potency. The results of an animal study 
support this view 7. However, the mutagenic potency of the creosotes can be higher than judged from the 
content of the surrogate agent, BaP alone. The finding that the fractions containing high concentrations 
of high molecular weight PAHs were less mutagenic than the creosotes, illustrates the difficulty of 
assessing the effects of a complex mixture. Creosotes obviously contain other compounds in addition to 
the identified PAHs, which enhance the mutagenic activity in the presence of S9 mix. The content of 
high molecular PAHs alone could not explain the mutagenic results of the creosotes in this study. 
Similarly, BaP content alone did not account for all the tumorigenic activity of complex mixtures, 
indicating that other components also contribute to the overall tumorigenic activity 184. Therefore, the 
EU regulation, that creosotes containing ≤ 50 ppm BaP shall not be labelled as carcinogenic, lacks a 
toxicological background. 
 
In addition to aromatic hydrocarbons, the creosotes contained sulphur, nitrogen and oxygen compounds. 
All the identified sulphur compounds were heterocyclic benzothiophenes or their derivatives. These and 
phenols have not been shown to have genotoxic activity 127. The contents of the identified nitrogen 
compounds in four analysed creosotes were somewhat lower (2.7-8.6 weight-%) than in a creosote (11 
weight-%) from the USA 21. Nitrogen compounds consisted of both heterocyclic and aromatic cyano- 
and amino-compounds (II). The content of nitrogen compounds was the highest in the Polish creosote, 
in contrast to the BaP content that was the lowest in it. Aminofluorenes were detected in all the analysed 
creosotes. The number of identified amino-PAHs in the creosote from the USA was higher than found in 
this study, which may due to the different analytical methods. Information on the mutagenicity of 
heterocyclic nitrogen compounds is scanty, but quinoline and its hydroxy compounds 155, and many 
amino-PAHs, e.g. 2-aminofluorene, are mutagenic 156, 157. The experiments with the bacteria strains 
YG1021 and YG1024, with the metabolic activation, revealed also the presence of aromatic amines 176.  
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In contrast to previous reports 153, emissions at 37 °C were not mutagenic in the taped plate assay (II). 
This result can be explained with the findings from the air monitoring study (I). The main components 
of the creosote emissions in impregnation plants and in the handling of treated wood were naphthalene, 
methyl naphthalenes, indene, phenol and its methyl homologues, benzothiophene, diphenyl, 
acenaphthene and fluorene, none of which are genotoxic. Also, over 90% of the particulate PAHs 
consisted of 3-ring PAH such as fluorene, phenanthrene and anthracene, which have showed 
inconsistent results in various genotoxicity experiments. These results indicate that the genotoxic 
potency of creosote emissions at temperatures below 35 °C is low. An exception was MMA welding of 
rails, where the temperature of the ties was clearly higher, and 50% of the particulate PAHs consisted of 
high molecular weight PAHs (4 - 6 aromatic rings). 
 
The mutagenicity of the end of shift urine samples of the impregnation plant workers was negative 177. 
This is in accordance with other studies, where no increase in mutagenic activity was found in urine of 
workers occupationally exposed to PAHs 3, 76, 91. The metabolites of non-genotoxic 2-3 ring PAHs e.g. 
those of naphthalene are excreted mainly in urine, whereas  genotoxic metabolites of 4-6 ring PAHs are 
mainly excreted in faeces 3. 
 
8.2. Exposure level 
In accordance with earlier industrial hygiene reports 25, 26, 79, the majority of airborne impurities were in 
the vapour phase. Over 99% of airborne impurities occurred as vapour both in the impregnation plants 
and in the handling of impregnated wood. In addition to diphenyl, naphthalene, methyl naphthalenes, 
and other volatile PAHs that have been identified in creosote vapours in an earlier study 25, 26, vapours 
contained e.g. methyl styrene, indene, phenol, methyl phenols, and heterocyclic compounds, such as 
benzothiophenes and dibenzofurane. The main components of the vapours were naphthalene and its 
alkyl derivatives. The ratio of naphthalene to the total concentration of vapour at the impregnation plants 
was 52%, and 32% in the handling of impregnated wood. The older the treated timber was, the lower 
was the percentage of naphthalene in the airborne impurities.  
 
There are very few earlier studies or industrial hygiene reports 25, 26, 81 in which the respiratory exposure 
of creosote workers to vapours and particles has been identified and measured. The concentration of 
airborne naphthalene in the tie plant was at the same level as measured in the Swedish impregnation 
plants at the beginning of the 1980s 25, 26, whereas the airborne naphthalene concentration measured in 
the same switch assembly hall in 1980 was higher than in the present study 81. The results of this study 
showed that the workers handling treated wood indoors were exposed to higher levels of airborne 
vapours than the impregnation plant workers on average. However, the exposure level of the 
impregnation plant worker who stayed near the cylinder and transported freshly treated timber was 
similar to that measured in the assembly hall in winter conditions. There was an approximately three-
fold difference between the two impregnation plants investigated, the higher concentrations occurring in 
the tie impregnation plant. The naphthalene content  in various creosotes (Polish/Soviet and German) 
used in the impregnation plants was approximately the same (9-11%); thus the difference in the airborne 
concentration was probably due more to the automated process and use of a local exhaust above the 
cylinder in the plant impregnating poles. Also the amount of stored timber was smaller in the pole plant 
than in the tie plant.  
 
Finnish OEL values have been established for naphthalene, diphenyl, phenol, cresols and indene of the 
identified vaporous compounds, and BaP of the particles in workroom air (Table 5). The measured 
TWA concentrations were low, less than 10% of the Finnish OELs. The concentration of BaP measured  
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during the MMA welding of rails is about 30% of the Swedish OEL. In spite of the low concentrations, 
the workers nevertheless complained of symptoms such as headache and irritation of the respiratory 
tract 140. 
 
The mean airborne concentration of BaP in the impregnation plant was 0.01 µg/m3, which is less than 
that measured in the other impregnation plants 25, 26, 79, 80. Also the airborne concentration of BaP in the 
assembly hall was slightly lower than the exposure level measured for the assemblers in 1983 81. The 
regulation of the BaP content in creosotes has probably not affected significantly on the airborne 
concentrations of carcinogenic PAHs since they already were low in the present study, but, on the other 
hand, the regulation helped to reduce the dermal exposure to BaP. 
 
There was only a weak correlation between the airborne concentrations of vapours and particulate 
PAHs. The emission of vapours is dependent on the age of the impregnated wood and the quantity of 
timber, whereas the emission of particulate PAHs depends mostly on the temperature of the wood and 
creosote. In the welding of rails, the sleepers were old, so the concentration of vaporous compounds in 
the air was low. The highest BaP concentrations were measured when the temperature of the 
impregnated sleepers reached several hundred degrees °C. 
 
The respiratory exposure of the impregnators and the workers handling treated wood to BaP (except 
welders) was several magnitudes of order lower than has been reported during the processing and use of 
coal products (Table 7). In the Finnish coking plant, the average concentration of BaP in air was 
2.5 µg/m3 in 1988, and after technical improvements 0.3 µg/m3 in 1994 62. The concentration of BaP in 
Finnish iron foundries was 5.1 µg/m3 on average when coal tar pitch was used 82. 
 
A linear relationship was found between the naphthalene concentration in air and 1-OHN in the urine of 
the impregnation plant workers (V), but the correlation was poor between the corresponding variables of 
the assemblers (IV). A linear correlation between the concentration of 1-OHN in the workers’ urine and 
the cocentration of naphthalene in air was found also in a coking plant 52. But the estimation of a 
biological exposure index for  urinary 1-OHN concentration, which would correspond to the Finnish 
OEL for naphthalene, is not feasible, since naphthalene is an indicator of exposure to a complex mixture 
and naphthalene is partly absorbed through the skin. 
 
No previous studies on the urinary 1-OHN concentrations in creosote workers were available. The 
arithmetic mean concentrations of 1-OHN in the end-of-shift urine of impregnation plant workers were 
1350 µmol/mol creatinine, and those of the tie assemblers 1330 µmol/mol creatinine. The corresponding 
1-OHN concentrations in the urine samples collected on Friday morning were 249 µmol/mol creatinine 
and 187 µmol/mol creatinine. After the importance of dermal exposure was recognised in the Finnish 
impregnation plants, the urinary 1-OHN concentrations of the impregnation plant workers have been 
surveyed by the occupational health service. The mean 1-OHN concentration in the morning urine 
samples collected on the 4th - 5th working day has been 116 µmol/mol creatinine in three impregnation 
plants in 1994-1999 94. Urinary 1-OHN concentrations have been monitored in the end-of-shift samples 
of workers engaged in other work tasks, e.g. in distillation workers of naphthalene oil (550-3400 
µmol/mol creatinine), in distillation workers of coal tars (700 µmol/mol creatinine), and among coking 
plant workers (3000 µmol/mol creatinine) 51, 52. One or two orders of magnitude lower levels of urinary 
1-OHN concentrations have been reported among iron foundry workers and  Finnish coking plant 
workers 53, 62. 
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The urinary concentrations of 1-OHP among the impregnation plant workers (64 µmol/mol creatinine) 
were similar to those measured in a Dutch impregnation plant (50-85 µmol/mol creatinine) in the 
1980s48, but 40 times higher than those reported among Canadian impregnation plant workers (1.6 
µmol/mol creatinine) in the 1990s 108. The arithmetic mean concentration of urinary 1-OHP among 
switch assemblers was about 10% of that among impregnation plant workers. Urinary 1-OHP 
concentrations which are as high as the ones measured among wood preservers in this study have not 
been reported in any other area of industry using coal or coal tar products (Table 7). Even the mean 
urinary 1-OHP concentrations among the workers handling newly treated (one year old) wood were at 
the same level or higher than the reported in aluminium or coking plant workers (Table 7). The TWA 
concentration of BaP in the air during the impregnation and handling of treated wood was only 1% of 
the level measured in the Finnish coking plant in 1988. By contrast, the mean urinary 1-OHP 
concentration was 100-fold higher in the impregnation plant workers than in the Finnish coking plant 
workers in 1988 62. The mean concentration of 1-OHP in the end-of-shift urine samples has been 
significantly lower (7.9 µmol/mol creatinine) in 1996-1998 87 than measured at the end of 1980s in the 
present study in the same tie plant.  
 
 
The urinary concentrations of 1-OHP did not correlate with pyrene or other PAH concentrations in air, 
contrary to other studies 56, 71, 86. The weak correlation was attributed to extensive dermal contamination 
and subsequent uptake of pyrene. 
 
The smoking habits of the workers in the tie impregnation plant did not affect their urinary 1-OHN or 1-
OHP concentrations. This finding is in agreement with the results of two studies among aluminium plant 
workers 5, 185. In many other studies, however, smokers have had higher urinary 1-OHP concentrations 
than could be explained by smoking, as observed among referents (Table 7). The higher cocentration of 
smokers may be due to several causes, e.g. smoking with contaminated fingers increases uptake, 
smoking may induce metabolic changes and smokers may take off their respirators more often than non-
smokers.  
 
8.3. Absorbed naphthalene and pyrene doses and dermal exposure 
In accordance with the literature 6, 43, 95, the estimated respiratory and dermal uptakes of naphthalene and 
pyrene confirm  the importance of skin as a route of entry for PAHs. The percutaneously absorbed dose 
constituted 55-70% of the total dose for naphthalene and over 99% for pyrene. Even though the dermal 
exposure route for pyrene has been dominant (50-90%) in the studies conducted among coking oven, 
creosote, and coal liquefaction workers, a percentage as high as the one detected in this study (over 
99%) has not been reported before 6, 43, 95. The amount of naphthalene absorbed through the skin among 
the workers in this study was higher than that of pyrene, although the relative importance of the 
percutaneous absorption of pyrene was much more significant than that of naphthalene. 
 
A dermal dose of 118 mg of naphthalene has resulted in a urinary 1-OHN concentration of 600-2600 
µmol/mol creatinine in psoriatic patients treated with coal tar ointment once a day for 4 weeks 88. 
Comparable results were obtained in the kinetic study: the dermal dose of 30-36 mg naphthalene 
resulted in a 1-OHN concentration of 300-550 µmol/mol creatinine (Figure 2). These results are in 
accordance with the estimation that the average urinary 1-OHN concentration of 1900 µmol/mol 
creatinine among the impregnation plant workers and that of 1300 µmol/mol creatinine among the 
assemblers were due to dermal exposure to 50 and 60 mg of naphthalene and to respiratory exposure to 
1.0 and 1.5 mg/m3 of naphthalene, respectively. The estimated total uptakes of naphthalene were 15-16 
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mg/day/worker for the impregnators and  the assemblers. The estimated dermal deposition of 
naphthalene was the same (55-60 mg/day/worker) for the assemblers and the impregnation plant 
workers. The dermal contamination and  
the total uptake of naphthalene among workers exposed to creosote have not been estimated before. No 
data are available on the estimated uptakes among other workers, either.   
 
The estimated total uptakes of pyrene, 0.6 - 5 mg/day/worker among the wood preservers and workers 
handling treated wood are from two to three orders of magnitude higher than the daily intakes measured 
(non-smoker 2 µg/day, smokers 4 µg/day) among the general population in the Netherlands 186, and 
much higher than the intakes estimated from ambient air (0.017-0.04 µg/day/person) 3. The total dietary 
intake of pyrene was estimated to be 1.1 µg/day/person in the UK 3. The estimated uptakes of the wood 
preserving workers were 10-fold higher than, and those of the assemblers of the same magnitude as the 
corresponding figures estimated for workers in an aluminium plant, a wood preserving plant and a 
coking plant (0.94, 0.69 and 0.14 mg/day), respectively 47. 
 
The highest urinary excretion of 1-OHP was generally detected in the evening urine samples (3.7-25.1 
µmol/mol creatinine in assemblers and 95-122 µmol/mol creatinine in wood preserving plant workers). 
This is in accordance with studies in which a delayed time (over 10 h delay) of maximum excretion of 
urinary 1-OHP has been detected after dermal exposure 116, 124. The maximum excretion of 1-OHN 
appeared in the end-of-shift urine samples among the creosote workers. In the kinetic study with pure 
naphthalene, the maximum excretion of 1-OHN was detected in the volunteers' urine 2-6 h after the 
cessation of the dermal exposure (Fig. 2). According to an animal study, complex coal tar mixes 
increase the dermal residence time of BaP 117.  
 
The estimated dermal exposures of pyrene (3-27 mg/worker) and the measured concentrations of the 
urinary metabolites are in good accordance with the results of the study on psoriatic patients in which 
the application of 14.3 mg/day of pyrene on the skin resulted in a 1-OHP urinary concentration of 60-
100 µmol/mol creatinine 88. 
 
Contamination of the skin is difficult to measure reliably for many reasons, and the estimates based on 
the total excretion of metabolites and the kinetics may be more reliable than the skin contamination 
measurements, e.g. by a surrogate skin method such as pads. This view is supported by Van Rooij, who 
concludes that the skin contamination measurements of pyrene carried out with pads underestimated the 
actual skin contamination by a factor of nine 47. The best estimates of skin contamination are achieved 
when both dermal exposure measurement and biological monitoring are carried out.  
 
The absorbed doses and dermal exposure to naphthalene and pyrene were estimated by applying both 
the results from this study (air concentrations, I, biological monitoring results, III-IV, and data from the 
kinetic study) and from the literature (pulmonary retention, respiration rate, absorption by ingestion, and 
ratio of excreted 1-OHP in urine). Interpretation of the results from dermal absorption studies on 
animals112, 121-123 or in vitro 119 to estimate the dermal absorption of PAHs was not possible because of 
the limited data, species differences and contradictory data. The kinetic study result, i.e. that 18% of the 
naphthalene was percutaneously absorbed, is of the same magnitude as van Rooij's finding for PAHs 
using the skin disappearance measurement technique with a luminoscope 124. The results of animal 
studies in which 14C-labelled compounds have been used to measure skin absorption of PAHs suggest 
that the variation between the dermal uptakes of naphthalene, pyrene and BaP is small 112, 121-123. Our 
assumption that  the dermally absorbed fraction of pyrene was equal to that of naphthalene was in 
agreement with the data of these animal studies. In contrast to the in vitro measured uptakes of 
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naphthalene, pyrene and BaP, however, the penetration rates of 2-5 ring PAHs have been found to 
depend on the molecular size of PAH 120.    
 
8.4. Excretion half-lives 
The calculated apparent half-lives exhibited a moderately rapid elimination phase (1-2 h for 1-OHN and 
5-6 h for 1-OHP), followed by the terminal phase with apparent half-lives of 14-46 h among the workers 
and 4-6 h in the volunteers (by ingestion) for 1-OHN and 22-24 h for 1-OHP. Considerable inter-
individual variation was found in the terminal half-lives for 1-OHN. The baseline (Monday morning) 
concentrations of 1-OHN and 1-OHP in urine increased during the work week and seemed to reach a 
steady state (IV, V). 
 
The calculated half-lives of 1-OHN were in fair agreement with those reported in another study 51. The 
apparent half-lives of the first phase (5-6 h) for 1-OHP was, however, shorter than generally quoted in 
the literature (6-35 h) 50, 96, 187. In many studies urine samples have been collected only before and after 
the shifts, and the half-lives could not be determined accurately. In such cases, half-lives may be 
overestimated when the maximum excretion rate takes place some hours after the end of the shift. 
 
Due to the relatively long terminal half-lives (over 12 h) of 1-OHN and 1-OHP, the steady state level 
was attained on the 3rd - 5th working day. Lafontaine reported a plateau in the urinary 1-OHP 
concentrations after three days of exposure among shooting target manufacturers 101. The slow second 
excretion phases and high exposure level explain the increase in the daily preshift samples during the 
work week. After the weekend on Monday morning, the urinary levels were still 10 times higher among 
the impregnation plant workers than in the assemblers' end-of-shift urine samples. Although our results 
showed accumulation of pyrene during the course of the work week, the results reported in the literature 
indicate that naphthalene and pyrene do not accumulate markedly in the body. In an animal study, the 
half-lives of pyrene in all tissues were 3.1-5.4 h and 5.2-6.7 h, indicating that no long-term accumulation 
would be predicted 131.  
 
8.5. Suitability of urinary 1-OHN and 1-OHP as a biomarker of PAH exposure 
The general population is exposed to naphthalene mainly by inhalation, and to pyrene by inhalation as 
well as orally. The main sources of exposure to naphthalene are ambient air (vehicle traffic and heating)3 
and tobacco smoke63. In addition to ambient air and tobacco smoke, pyrene is obtained via diet 3, 186. The 
urinary concentration of the Finnish reference groups was far below the concentrations measured among 
the wood preservers and the workers handling treated wood. Smoking did not increase urinary 
concentrations of 1-OHN or 1-OHP among the workers in the impregnation plant when compared to the 
levels among non-smokers. Thus the urinary concentrations of 1-OHN and 1-OHP served as indicators 
of occupational exposure. 
 
The aim of monitoring airborne contaminants and urinary 1-OHN and 1-OHP concentrations was to 
assess the exposure to PAHs. In the air measurements, the concentration of 10-20 PAHs is generally 
monitored to assess respiratory exposure to a complex mixture of PAHs. In biological monitoring, in 
most of the studies the urinary concentration of one metabolite, 1-OHP has been used as a biomarker of 
PAH exposure (Table 7). In this study, the concentrations of two metabolites were monitored. 
Naphthalene was selected as a marker compound for biological monitoring, because it is the main 
component of airborne PAHs, and pyrene as an indicator for 4 -6 ring PAHs. Current analytical methods 
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are not sensitive enough to determine small quantities of BaP metabolites in the urine of occupationally 
exposed workers 57, 58.  
 
The air concentration of naphthalene correlated well with the total vapour concentration. Naphthalene is 
thus a fair indicator of exposure to airborne 2-3 aromatic ring PAHs. The respiratory absorption of 
naphthalene constituted about 50% of the total uptake. The results of this study show that the urinary 1-
OHN concentration can be used as a marker compound of the respiratory and dermal exposure to 
naphthalene. But due to the dominant uptake of naphthalene via inhalation, and the poor correlation 
between naphthalene and particulate airborne PAHs, urinary 1-OHN is not a reliable indicator of 
exposure to 4-6 aromatic ring PAHs which enter the body mainly through the skin. Urinary 1-OHP was 
mainly a biomarker of cutaneous absorption of pyrene among the creosote workers, inhaled pyrene 
explaining less than 1% of the measured internal dose. It is not well known whether this metabolite is a 
reliable biomarker to be used for the quantitative estimation of dermal absorption of other PAH 
compounds such as BaP in a complex mixture. The results of some animal studies indicate that the 
fraction dermally absorbed is the same for naphthalene, pyrene and BaP, when the penetration is 
followed for several days 112, 121-123. However, the results from in vitro studies suggest that the skin 
penetration rates of 2-3 ring PAHs, pyrene and 5 ring PAHs differ from each other manyfold, and the 
penetration rates depend on the molecular size of PAHs 119, 120. On the other hand, DNA-adducts of 
PAHs have been detected in the lungs of experimental animals after dermal application of coal tar 77, 78. 
Furthermore, topical treatment with creosote increased the frequency of lung cancer in animals 2. 
Although there is not enough knowledge to estimate quantitatively the absorbed doses of carcinogenic 
PAHs from urinary 1-OHP concentrations, these biological monitoring data shed light on the possible 
significant exposure to carcinogenic PAHs.  
 
In agreement with animal data from the literature 73, 130 the results of the kinetic study on naphthalene 
show that the ratio between the applied dose and the excreted metabolite depends on the route of intake. 
The activities of mono-oxygenase enzymes expressed in the liver may differ from those in the lungs and 
on the skin 3. The excretion of 1-OHN was significantly higher after ingestion than after the intake by 
other routes in this study. A part of inhaled particulate bound PAHs are also swallowed; mucociliary 
clearance quickly removes particles from the thoracic airways, and a varying fraction of the inhaled 
particles are ingested 114. Thus the urinary concentration of 1-OHP among workers exposed via 
inhalation to particulate pyrene results from the absorption and excretion from the respiratory tract into 
the gastrointestinal tract. This may explain the high ratio of the excreted 1-OHP to the absorbed pyrene 
reported among coking and aluminium plant workers 6, 113.  
 
Animal and human  studies show that the metabolite pattern of PAHs and mass relationships between 
the inhaled PAHs and the metabolites excreted can differ significantly from one individual to another 54, 
58, 128, but that intraindividual variation is small 128. In spite of invariances between individuals, the 
biomonitoring results of this study nevertheless show that the exposure of creosote workers to pyrene 
was high. Interindividual variances in the metabolism of PAHs may, however, make the estimation of 
external exposure and internal doses inaccurate, e.g. in assessing which worker has the highest exposure.  
 
It is difficult to compare the exposure levels in different work environments based on the concentrations 
of urinary 1-OHN and 1-OHP.  Naphthalene and pyrene or their urinary 1-hydroxy metabolites are used 
as surrogates to estimate the exposure to PAHs. The percentage of naphthalene and pyrene in total PAH 
or in comparison with BaP in air varies in different industries 36, 71, 90, 96. Correspondingly, their fraction 
in the materials contaminating the skin varies, as shown in this study. Therefore, the usefulness of 1-
OHN and 1-OHP as biomarkers of PAH exposure lies primarily within the same industrial areas. In 
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addition, the analysis of the concentration of urinary metabolites does not give information on the 
exposure route. Thus monitoring of the airborne substances and dermal contamination is needed to draw 
conclusions on the importance of different exposure routes. 
 
In some studies the difference between the end-of-shift and morning urine 1-OHP concentrations have 
been used as a measure of exposure during the work day 98, 188. According to the results of the present 
study, this difference is not a valid indicator of naphthalene and pyrene exposure, partly because of the 
delayed absorption via the skin and partly due to the long terminal half-lives of these substances. The 
steady state of urinary 1-OHN and 1-OHP will be attained on the 3rd - 5th working day. The urinary 
concentration measured at the end of the shift reflects the total exposure on the same work day and the 
body burden of the previous day, whereas the concentration measured in the morning urine at the end of 
the work week reflects the body burden of the previous day and work week.  
 
8.6. Control strategies and recommendations 
This study confirmed that absorption through the skin is the main route of entry of naphthalene and 
pyrene, and thus the reduction of dermal exposure is an important measure for controlling occupational 
exposure. The prevention of dermal exposure and percutaneous absorption may be accomplished by 
several means: the design of the work process and work practices, the use of protective clothing, general 
hygiene and safety, education and surveillance. After dry-cleaning, the content of 11 PAHs in the 
worker's overalls was 1.5 µg/cm2, when it was 190 µg/cm2 after washing the overalls with water and 
detergents 140. Therefore, overalls and contaminated underwear should be dry-cleaned. 
 
After the present study was completed, the company that impregnated railway ties has implemented the 
following strategy to control PAH exposure:  
- The plating of railway sleepers is performed before impregnation, and consequently dermal exposure 
of the tie platers is minimised 
- Chemical laundering of overalls  
- Protection of the skin with grease and gloves  
- Educating and informing of workers on the exposures and possible health effects, on the importance of 
clean underwear and washing the skin, and prohibiting smoking while applying wood preservatives 
- Biological monitoring of exposed workers  
- Ties are warmed before impregnation, which reduces effusion.  
As a result of these actions, the urinary 1-OHP concentrations of the workers in the tie plant have been 
one order of magnitude lower (1.3-9.2 µmol/mol creatinine) in 1998 87 than detected in the present 
study. 
 
To get knowledge on the level and route of exposure among creosote workers, the following strategy 
should be followed: measurement of the concentrations of airborne impurities, dermal exposure 
assessment,  biological monitoring of PAH metabolites, and preferably also data on the composition of 
the used products. 
 
Information on the composition of creosotes can be requested from the manufacturer. The measurements 
of airborne impurities can be carried out by sampling vapours on XAD-2 adsorbent, and particles on a 
PTFE filter. Vaporous compounds can be analysed by HRGC with a MS or FID detector. At least the 
airborne concentrations of naphthalene, diphenyl and 2-3 ring PAHs should be quantified. The 
concentrations of vaporous PAH can be analysed also by HPLC with a fluorescence detector. However, 
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only PAHs can be detected by this method, not e.g. diphenyl. The analysis of particles on filters can be 
carried out by HPLC with a fluorescence detector or by HRGC.  
 
Assessing dermal exposure is a complex task. All the existing dermal contamination sampling 
methods 45 can be used to assess the dermal exposure of creosote workers. However, there is great 
uncertainty in the methods and strategies used in the sampling, as well as assessment of the results 189. 
Dermal exposure measurements give data on the amount of contaminants on the skin. Measurement of 
dermal exposure in combination with dermal exposure assessment can be used to determine exposure 
pathways and to develop hazard control strategies.  
 
Based on the poor data on the dermal absorption of different PAHs and great interindividual variation in 
PAH metabolism, no quantitative estimations can be given on how well the concentrations of the urinary 
1-OHN and 1-OHP predict dermal absorption of other PAHs. When airborne PAHs are measured, 
currently concentrations of about 16 PAHs are quantified 190. Correspondingly, the concentration of 
several urinary metabolites would describe the exposure more accurately than that of only 1-2 
metabolites. Methods to measure urinary metabolites of fluoranthene, phenanthrene, chrysene and BaP 
have been described in the literature 55, 58, 130. However, the concentration of urinary metabolites of BaP 
among occupationally exposed workers has been very low, below the detection limit of the most 
analytical methods used.   
 
The results of this study showed that pyrene entered the body mainly through the skin and, in spite of 
possible interindividual variation, that the urinary concentration of 1-OHP was very high when 
compared to other industries where coal or coal tar is used (Table 7). Thus the measurement of urinary 
metabolites is important for exposure assessment and risk management purposes. The concentrations 
measured in the morning urine samples collected on the 4th - 5th working day give information on the 
exposure level during the previous days. However, due to possible metabolic variation between 
individuals, the concentrations of urinary metabolites do not necessarily tell which worker has the 
highest external exposure.   
 
Data in the literature show that the dermal uptake of BaP is not higher than that of pyrene, and that after 
topical application, experimental animals have had genotoxic changes and cancer in inner organs 78. 
Thus, for occupational exposure and risk management purposes, one can assume, until better knowledge 
is available, that the relative dermal absorption of BaP is not higher than that of pyrene.  
 
There are no biological action levels for 1-OHN or 1-OHP in urine in Finland. At present, it is not 
feasible to establish biological indices for 1-OHN and 1-OHP which are valid for all work places. The 
goal of control measures should be to avoid exposure to carcinogenic substances, and to reduce skin 
contamination and urinary concentrations of metabolites to as low levels as practicable.  
 
Naphthalene and pyrene, and probably also other PAHs, are easily absorbed through the skin. It is thus 
strongly recommended to add the skin notation to the Finnish OELs of naphthalene and BaP. 
Summary and Conclusions   
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Summary and Conclusions 
1. The composition of the creosotes used in Finland has not been studied in detail earlier. The 
composition of the materials used must be known, however, in order to estimate the exposure and its 
possible health effects. Coal tar creosotes, used in wood impregnation, are complex mixtures of 
aromatic and heterocyclic hydrocarbons. In accordance with the literature, the composition of the 
creosotes with different origins varied widely, but the concentration of PAHs in all creosotes was high, 
over 60%. Altogether 85 compounds were analysed semiquantitatively. All creosotes were mutagenic in 
the Ames Salmonella tests in the presence of metabolic activation, as could be expected on the basis of 
the literature. The potency of the mutagenicity correlated with the content of benzo(a)pyrene (BaP), and 
also the creosote with the lowest content of BaP (50 ppm) was mutagenic. The mutagenicity of the 
creosotes was nevertheless higher than that of the distillation fractions containing mutagenic PAHs. This 
suggests that lowering the BaP content can reduce the mutagenic and probably also carcinogenic 
potency of creosotes. However, since creosotes contain other mutagenic and carcinogenic compounds 
besides BaP, the lowering of the BaP content even close to zero level probably does not reduce the 
mutagenicity and carcinogenicity. 
 
2. The kinetics of naphthalene metabolism, after intake by different routes into the human body has not 
been studied before. The results of the pilot kinetic study with two volunteers confirmed that 
naphthalene enters the body by all routes of exposure - also the skin is a significant route of exposure - 
and that the fraction of naphthalene excreted in urine as 1-OHN depends on the route of exposure. 
According to the literature, the PAH metabolism varies significantly between individuals. Thus the 
results from the two volunteers give only suggestive figures which may or may not represent the 
majority of people.  
 
3. The study provided new data on the composition of airborne impurities which creosote workers are 
exposed to, and on the level of respiratory exposure. The workers were exposured via the lungs to 
airborne impurities that contained over 95% vaporous compounds and less than 5% particulate PAHs. 
The main components of the 28 identified airborne compounds were naphthalene, its alkyl homologues, 
indene, phenol, benzothiophene and diphenyl. In agreement with the literature, the average respiratory 
exposure of the workers to particulate benzo(a)pyrene in the impregnation plants was low (0.01 µg/m3). 
A new finding was that BaP concentrations were low also in handling of treated wood, except when the 
creosote or treated wood was heated; in such conditions the concentration of BaP in air was as high as 
0.89 µg/m3.  
 
In this study two indicator compounds, i.e. urinary 1-OHN and 1-OHP, were measured to assess the 
respiratory and dermal exposure to PAHs. In most studies, the PAH exposure has been assessed from 
the urinary 1-OHP. The urinary concentrations of 1-OHN have not been studied before among creosote 
workers. The biomonitoring data showed that average respiratory and dermal exposure levels to 
naphthalene were equally high among the impregnation plant workers and the assemblers handling 
freshly impregnated wood. On the other hand, the total exposure of the impregnation workers to pyrene 
was 10 times higher than that of the assemblers. The urinary  1-OHP levels of the impregnation plant 
workers were higher than those reported in the literature in coking and aluminium plant workers who 
were shown to have an increased cancer risk. The urinary  1-OHP levels of the assemblers were also 
high, at the level generally described in these industries. 
 
4. The estimations based on the daily output of the urinary 1-OHN and 1-OHP and the daily inhaled 
uptake of naphthalene and pyrene suggest that 50-60% of the naphthalene taken up, and over 99% of 
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pyrene were absorbed percutaneously. Although the dermal exposure route has been found to be 
dominant among coal and coal tar workers in the literature, a percentage as high as the one detected in 
this study for pyrene, has not been reported previously.   
 
5. As could be expected from the literature, the results of this study showed that the urinary 
concentrations of 1-OHN and 1-OHP are better indicators of respiratory and dermal exposure to 
creosote than the measurement of airborne impurities, because they reflect also dermal exposure. The 
suitability of urinary 1-OHN and 1-OHP as biomarkers of PAH exposure depends on how well they 
predict the uptake of other PAHs. The creosote workers are exposed to 4-6 ring PAHs mainly when they 
are in contact with creosote or impregnated wood. Earlier research suggests that the total percentages of 
dermally absorbed naphthalene, pyrene and BaP do not differ significantly if followed for several days, 
but that the penetration rates of PAHs depend on the size of the molecule. More knowledge is needed to 
estimate whether urinary 1-OHP is a reliable biomarker for quantitative calculation of dermal absorption 
for other 4 -6 aromatic ring PAHs, e.g. for BaP. However, previous data show that the dermal uptake of 
BaP is not higher than that of pyrene and that after topical application, experimental animals have had 
genotoxic changes and cancers of the inner organs. For occupational exposure assessment and risk 
management purposes, one can therefore assume that the relative dermal absorption of BaP is not higher 
than that of pyrene
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